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1. 
SOLATION OF BINDING PROTEINS WITH 
HIGH AIFFINITY TO LIGANDS 
The government owns rights in the invention pursuant to 
DARPA Grant No. MDA(972-97-0009). 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates generally to the field of 
protein engineering. More particularly, it concerns methods 
for the screening of combinatorial libraries of polypeptides 
to allow isolation of enzymes having a desired catalytic 
activity and of ligand binding proteins, including antibodies 
and binding proteins having affinity for selected ligands 
2. Description of Related Art 
The isolation of proteins that either bind to ligands with 
high affinity and specificity or catalyze the enzymatic con 
version of a reactant (Substrate) into a desired product is a 
key process in biotechnology. Ligand-binding proteins and 
enzymes with a desired substrate specificity can be isolated 
from large libraries of mutants, provided that a suitable 
screening method is available. Small protein libraries com 
posed of 10–10 distinct mutants can be screened by first 
growing each clone separately and then using a conventional 
assay for detecting clones that exhibit specific binding. For 
example, individual clones expressing different protein 
mutants can be grown in microtiter well plates or separate 
colonies on semisolid media Such as agar plates. To detect 
binding the cells are lysed to release the proteins and the 
lysates are transferred to nylon filters, which are then probed 
using radiolabeled or fluorescently labeled ligands (DeWildt 
et al. 2000). However, even with robotic automation and 
digital image systems for detecting binding in high density 
arrays, it is not feasible to Screenlarge libraries consisting of 
tens of millions or billions of clones. The screening of 
libraries of that size is required for the de novo isolation of 
enzymes or protein binders that have affinities in the nano 
molar range. 
The screening of very large protein libraries has been 
accomplished by a variety of techniques that rely on the 
display of proteins on the surface of viruses or cells (Ladner 
et al. 1993). The underlying premise of display technologies 
is that proteins engineered to be anchored on the external 
Surface of biological particles (i.e., cells or viruses) are 
directly accessible for binding to ligands without the need 
for lysing the cells. Viruses or cells displaying proteins with 
affinity for a ligand can be isolated in a variety of ways 
including sequential adsorption/desorption form immobi 
lized ligand, by magnetic separations or by flow cytometry 
(Ladner et al. 1993, U.S. Pat. No. 5,223,409, Ladner et al. 
1998, U.S. Pat. No. 5,837,500, Georgiou et al. 1997, Shusta 
et al. 1999). The most widely used display technology for 
protein library screening applications is phage display. 
Phage display is a well-established and powerful technique 
for the discovery of proteins that bind to specific ligands and 
for the engineering of binding affinity and specificity (Rodi 
and Makowski, 1999). In phage display, a gene of interest is 
fused in-frame to phage genes encoding Surface-exposed 
proteins, most commonly pII. The gene fusions are trans 
lated into chimeric proteins in which the two domains fold 
independently. Phage displaying a protein with binding 
affinity for a ligand can be readily enriched by selective 
adsorption onto immobilized ligand, a process known as 
“panning. The bound phage is desorbed from the surface, 
usually by acid elution, and amplified through infection of E. 














are sufficient to select for phage displaying specific polypep 
tides, even from very large libraries with diversities up to 
10 Several variations of phage display for the rapid enrich 
ment of clones displaying tightly binding polypeptides have 
been developed (Duenas and Borrebaeck, 1994; Malmborg 
et al., 1996; Kjaer et al., 1998: Burioni et al., 1998: Levitan, 
1998; Mutuberria et al., 1999; Johns et al., 2000). 
One of the most significant applications of phage display 
technology has been the isolation of high affinity antibodies 
(Dall’ Acqua and Carter, 1998; Hudson et al., 1998: Hoo 
genboom et al., 1998; Maynard and Georgiou, 2000). Very 
large and structurally diverse libraries of sclv or FAB 
fragments have been constructed and have been used Suc 
cessfully for the in vitro isolation of antibodies to a multi 
tude of both synthetic and natural antigens (Griffiths et al., 
1994; Vaughan et al., 1996; Sheets et al., 1998; Pini et al., 
1998; de Haard et al., 1999: Knappik et al., 2000; Sblattero 
and Bradbury, 2000). Antibody fragments with improved 
affinity or specificity can be isolated from libraries in which 
a chosen antibody had been Subjected to mutagenesis of 
either the CDRs or of the entire gene CDRs (Hawkins et al., 
1992: Low et al., 1996: Thompson et al., 1996; Chowdhury 
and Pastan, 1999). Finally, the expression characteristics of 
sch V, notorious for their poor solubility, have also been 
improved by phage display of mutant libraries (Deng et al., 
1994; Coia et al., 1997). 
However, several spectacular successes notwithstanding, 
the screening of phage-displayed libraries can be compli 
cated by a number of factors. First, phage display imposes 
minimal selection for proper expression in bacteria by virtue 
of the low expression levels of antibody fragment gene III 
fusion necessary to allow phage assembly and yet sustain 
cell growth (Krebber et al., 1996, 1997). As a result, the 
clones isolated after several rounds of panning are fre 
quently difficult to produce on a preparative scale in E. coli. 
Second, although phage displayed proteins may bind a 
ligand, in some cases their un-fused soluble counterparts 
may not (Griep et al., 1999). Third, the isolation of ligand 
binding proteins and more specifically antibodies having 
high binding affinities can be complicated by avidity effects 
by virtue of the need for gene III protein to be present at 
around 5 copies per virion to complete phage assembly. 
Even with systems that result in predominantly monovalent 
protein display, there is nearly always a Small fraction of 
clones that contain multiple copies of the protein. Such 
clones bind to the immobilized surface more tightly and are 
enriched relative to monovalent phage with higher affinities 
(Deng et al., 1995; MacKenzie et al., 1996, 1998). Fourth, 
theoretical analysis aside (Levitan, 1998), panning is still a 
“black box” process in that the effects of experimental 
conditions, for example the stringency of Washing steps to 
remove weakly or non-specifically bound phage, can only be 
determined by trial and error based on the final outcome of 
the experiment. Finally, even though pII and to a lesser 
extent the other proteins of the phage coat are generally 
tolerant to the fusion of heterologous polypeptides, the need 
to be incorporated into the phage biogenesis process 
imposes biological constraints that can limit library diver 
sity. Therefore, there is a great need in the art for techniques 
capable of overcoming these limitations. 
Protein libraries have also been displayed on the surface 
of bacteria, fungi, or higher cells. Cell displayed libraries are 
typically screened by flow cytometry (Georgiou et al. 1997, 
Daugherty et al. 2000). However, just as in phage display, 
the protein has to be engineered for expression on the cell 
surface. This imposes several potential limitations. First of 
all, either the N-terminal or the C-terminal of the protein has 
US 7,083,945 B1 
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to be fused to a vehicle for display. Thus, these technologies 
are not suitable where the N- or C-termini are essential for 
ligand binding. Second, the requirement for display of the 
protein on the Surface of a cell imposes biological con 
straints that limit the diversity of the proteins and protein 
mutants that can be screened. Third, complex proteins 
consisting of several polypeptide chains cannot be readily 
displayed on the Surface of bacteria, filamentous phages or 
yeast. As such, there is a great need in the art for technology 
which circumvents all the above limitations and provides an 
entirety novel means for the screening of very large polypep 
tide libraries. 
At present, the isolation of novel enzymes from libraries 
of protein mutants is typically accomplished either through 
the use of a phenotypic selection or screening in either Solid 
phase or microtiter well plates. Biological selections are 
based on complementation of auxotrophy or resistance to 
cytotoxic agents (e.g., antibiotics). Unfortunately, the utility 
of phenotypic selections is limited to the isolation of cata 
lysts for reactions that are of direct biological relevance or 
can be indirectly linked to a selectable phenotype. Alterna 
tively, each clone in a mutant population may be screened 
directly for enzymatic activity. For libraries expressed in 
microorganisms, screening can be performed on colonies 
growing on a solid Substrate such as agar. Solid phase 
screening relies on Substrates of an enzymatic reaction that 
give rise to a Zone of clearance, a fluorescent product, or a 
strongly absorbing (chromogenic) product. The assay may 
detect the enzyme product directly or may be coupled to a 
second enzyme whose product can in turn be easily moni 
tored. However, many assays cannot be implemented in a 
solid phase format. If that is the case then individual clones 
must be grown and assayed in microtiter wells. Such assays 
are significantly more time consuming than Solid phase 
assays and severely limit the number of mutants that can be 
screened. However, when a small number of random 
mutants is screened, the probability of finding clones 
expressing an enzyme that can catalyze a desired biotrans 
formation, especially when that biotransformation requires a 
complicated reaction, is severely affected. 
In general, methods that will allow the screening of large 
libraries of enzyme mutants on the basis of kinetic param 
eters, i.e., on the basis of how much product is generated per 
unit time, are needed. Phage display technology may in 
principle be used as a tool for the isolation of useful enzymes 
from large libraries. However, harnessing phage display 
technology for the isolation of enzyme catalysts from librar 
ies has thus far not proven practical (Olsen et al. 2000). For 
example there is no apparent way to physically link in a 
quantitative manner a phage particle displaying a certain 
enzyme clone with the outcome of multiple catalytic turn 
overs resulting in the accumulation of reaction product. 
Establishing Such a linkage is essential for the screening of 
protein libraries on the basis of catalytic proficiency. 
SUMMARY OF THE INVENTION 
In one aspect, the invention provides a method of obtain 
ing a bacterium comprising a nucleic acid sequence encod 
ing a binding protein capable of binding a target ligand, the 
method comprising the steps of: (a) providing a Gram 
negative bacterium comprising a nucleic acid sequence 
encoding a candidate binding protein, wherein the binding 
protein is expressed in soluble form in the bacterium; (b) 
contacting the bacterium with a labeled ligand capable of 
diffusing into the bacterium; and (c) selecting the bacterium 













bacterium, wherein the ligand and the candidate binding 
protein are bound in the bacterium. 
In another aspect, the invention provides a method of 
obtaining a nucleic acid sequence encoding a binding pro 
tein capable of binding a target ligand, the method compris 
ing the step of: (a) providing a Gram negative bacterium 
comprising a nucleic acid sequence encoding a candidate 
binding protein, wherein the binding protein is expressed in 
soluble form in the bacterium; (b) contacting the bacterium 
with a labeled ligand capable of diffusing into the bacterium; 
(c) selecting the bacterium based on the presence of the 
labeled ligand within the bacterium, wherein the ligand and 
the candidate binding protein are bound in the bacterium; 
and (d) cloning the nucleic acid sequence encoding the 
candidate binding protein. 
In another aspect of the invention, the binding protein 
expressed in the bacterium is further defined as expressed in 
soluble form in the periplasm of the bacterium. The nucleic 
acid sequence encoding the binding protein may still further 
be defined as encoding a nucleic acid sequence comprising 
the candidate binding protein sequence operably linked to a 
leader sequence capable of directing expression of the 
candidate binding protein in the periplasm. Potentially any 
Gram negative bacterium could be used with the invention, 
including, for example, an E. coli bacterium. In one embodi 
ment of the invention, the nucleic acid sequence encoding a 
candidate binding protein may be further defined as capable 
of being amplified following the selection. The invention 
may still further be defined as including removing labeled 
ligand not bound to the candidate binding protein. 
In yet another aspect, the invention comprises providing 
a population of Gram negative bacteria. In one embodiment 
of the invention, the population of bacteria is further defined 
as collectively capable of expressing a plurality of candidate 
binding proteins. In yet another embodiment of the inven 
tion, the population of bacteria is obtained by a method 
comprising the steps of: a) preparing a plurality DNA inserts 
which collectively encode a plurality of different potential 
binding proteins, and b) transforming a population of gram 
negative bacteria with the DNA inserts. The population of 
Gram negative bacteria may be still further defined as 
contacted with the labeled ligand. 
In still yet another aspect of the invention, a candidate 
binding protein employed in accordance with the invention 
is further defined as an antibody or fragment thereof, or 
alternatively, is a binding protein other than an antibody. 
Still further, the candidate binding protein may be an 
enzyme, including any portion thereof A candidate binding 
protein used with the invention may be further defined as not 
capable of diffusing out of the periplasm in intact bacteria. 
In still yet another aspect of the invention, a labeled ligand 
may comprise a polypeptide, an enzyme and/or a nucleic 
acid or the like. The labeled ligand may be further defined 
as comprising a molecular weight of less than about 20,000 
Da, less than about 10,000 Da or less than about 5,000 Da, 
and may in other embodiments of the invention be described 
as greater than 600 Da in molecular weight. The labeled 
ligand may be still further defined as fluorescently labeled. 
In still yet another aspect, the invention comprises treat 
ing a bacterium to facilitate diffusing of a target ligand into 
the periplasm. In certain embodiments of the invention, the 
treating may comprise use of hyperosmotic conditions, 
physical stress, treating the bacterium with a phage, or 
growing the bacterium at a Sub-physiological temperature, 
for example, about 25°C. 
In still yet another aspect, the invention comprises select 
ing one or more bacteria using FACS or magnetic separa 
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tion. In the invention, the ligand and candidate binding 
protein may be further defined as reversibly bound in the 
periplasm. 
In still yet another aspect, the invention provides a method 
of obtaining a bacterium comprising a nucleic acid sequence 
encoding a catalytic protein catalyzing a chemical reaction 
involving a target Substrate, the method comprising the steps 
of: (a) providing a Gram negative bacterium comprising a 
nucleic acid sequence encoding a candidate catalytic pro 
tein, wherein the catalytic protein is expressed in soluble 
form in the bacterium; (b) contacting the bacterium with a 
target Substrate capable of diffusing into the bacterium, 
wherein the candidate catalytic protein catalyzes a chemical 
reaction involving the target Substrate and wherein the 
chemical reaction yields at least a first Substrate product; and 
(c) selecting the bacterium based on the presence of the first 
Substrate product. In yet another aspect of the invention, the 
method may be further defined as a method of obtaining a 
nucleic acid sequence encoding a catalytic protein cata 
lyzing a reaction with a target Substrate, the method further 
comprising the step of (d) cloning the nucleic acid sequence 
encoding the candidate catalytic protein. By "catalytic pro 
tein’ it is meant a molecule which is capable of increasing 
the rate of a chemical reaction relative to the rate the reaction 
would occur absent the catalytic protein. In the method, the 
candidate catalytic protein may be expressed in soluble form 
in the periplasm of the bacterium. The nucleic acid sequence 
encoding a candidate catalytic protein may, in further 
embodiments of the invention, be defined as operably linked 
to a leader sequence capable of directing expression of the 
candidate catalytic protein in the periplasm. 
In still yet another aspect, the aforementioned method 
may be carried out with any Gram negative bacterium, for 
example, an E. coli bacterium. The invention may also 
comprise providing a population of Gram negative bacteria. 
The population may be further defined as collectively 
capable of expressing a plurality of candidate catalytic 
proteins. In one embodiment of the invention, the population 
of bacteria is obtained by a method comprising the steps of 
a) preparing a plurality DNA inserts which collectively 
encode a plurality of different candidate catalytic proteins, 
and b) transforming a population of Gram negative bacteria 
with the DNA inserts. The Gram negative bacteria may be 
defined as contacted with the target substrate. A bacterium 
selected with the invention may be further defined as viable 
following the selecting. Selecting may be carried out by any 
desired method, for example, FACS or magnetic separation. 
In still yet another aspect of the invention, a candidate 
catalytic protein is an enzyme. The candidate catalytic 
protein may also be defined as not capable of diffusing out 
of the periplasm. 
In still yet another aspect of the invention, a target 
Substrate may comprise a molecule containing a scissile 
amide bond. The target Substrate may also comprise a 
polypeptide or a nucleic acid. In certain embodiments of the 
invention, the target Substrate comprises a molecule con 
taining a Scissile carboxylic ester bond, a molecule contain 
ing a scissile phosphate ester bond, a molecule containing a 
Scissile Sulfonate ester bond, a molecule containing a scissile 
carbonate ester bond, a molecule containing a Scissile car 
bamate bond, and/or a molecule containing a scissile 
thioester bond. In still further embodiments of the invention, 
the target Substrate is further defined as comprising a 
molecular weight of less than about 20,000 Da, less than 
about 5,000 Da, less than about 3,000 Da, or may be defined 
as comprising a molecular weight of greater than about 600 













In still yet another aspect of the invention, the first 
substrate product is further defined as capable of being 
detected based on the presence of a fluorescent signature. 
This fluorescent signature may be absent in the target 
Substrate, and may only be produced upon chemical reaction 
to produce the first substrate product. In one embodiment of 
the invention, a fluorescent signature is produced by cata 
lytic cleavage of a scissile bond. The method may be further 
defined as comprising use of a FRET system, the FRET 
system comprising a fluorophore bound by a scissile bond to 
at least a first molecule capable of quenching the fluores 
cence of the fluorophore, wherein cleavage of the scissile 
bond allows the first molecule to diffuse away from the 
fluorophore and wherein the fluorescence of the fluorophore 
becomes detectable. In the method, the fluorophore may 
comprise a positive charge allowing the fluorophore to 
remain associated with the bacterium. In further embodi 
ments of the invention, the target substrate may be further 
defined as comprising a latent fluorescent moiety capable of 
being released by the chemical reaction involving the target 
substrate. The latent fluorescent moiety released by the 
cleavage may possess an overall positive charge allowing 
the moiety to remain associated with the bacterium follow 
ing the cleavage. In yet another embodiment of the inven 
tion, the method may comprise labeling the target Substrate 
with a fluorescent pH probe capable of being detected upon 
a change in pH associated with the chemical reaction 
involving the target substrate. The fluorescent pH probe may 
possess an overall positive charge allowing the fluorescent 
pH probe to remain associated with the bacterium following 
the chemical reaction involving the target substrate. It will 
be understood by those of skill in the art that multiple 
products may be produced as a result of the chemical 
reaction and any one or more of these could potentially be 
detected to reveal that occurrence of the chemical reaction. 
Accordingly, the reaction product may comprise a change in 
pH within the bacterium which could be detected. 
In still yet another aspect, the invention may comprise 
treating the bacterium to facilitate the diffusing into the 
periplasm, for example, using hyperosmotic conditions, 
physical stress, treating the bacterium with a phage, and 
growing the bacterium at a Sub-physiological temperature, 
for example, about 25°C. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present specifi 
cation and are included to further demonstrate certain 
aspects of the present invention. The invention may be better 
understood by reference to one or more of these drawings in 
combination with the detailed description of specific 
embodiments presented herein. 
FIG. 1. General scheme of the basis of a preferred 
embodiment of the invention. A library of proteins expressed 
in the periplasmic space of bacteria is contacted with a 
fluorescent reagent. Bacterial clones expressing a protein 
having a desired activity (e.g., either binding of the probe or 
enzymatic conversion to a product) become fluorescently 
labeled. The fluorescent cells can subsequently be isolated 
by FACS. 
FIGS. 2A-2C. Isolation of affinity improved mutants of 
an anti-digoxin antibody by two rounds of Sorting. A library 
of scFv mutants in which three residues in the light chain 
had been randomized was constructed as described in 
Example 2. A total of 2.5x10° transformants were grown in 
liquid media, labeled with 100 nM digoxin-BODIPYTM and 
fluorescent cells falling within the window shown in the 
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rightmost panel were sorted by FACS. The sorted cells were 
grown in liquid media, re-labeled and cells falling within the 
specified window as shown in the center panel were isolated. 
Following a final round of re-growth the cells were analyzed 
by FACS (FIG. 2A). Single schv antibody colonies were 
picked at random, analyzed and the affinity of the corre 
sponding scEv proteins are reported in Table 1. 
FIGS. 3A-3H. Shows strain dependence of periplasmic 
FACS signal: FIG. 3A TG1/pHEN2.thy: FIG. 3C HB2151/ 
pHEN2.thy: FIG. 3E ABLETMC/pHEN2.thy: FIG. 3G 
ABLETMK/pHEN2.thy; FIG. 3B TG1/pHEN2.dig: FIG. 3D 
HB2151/pHEN2.dig: FIG. 3F ABLETMC/pHEN2.dig: FIG. 
3H ABLETMK/pHEN2.dig. 
FIGS. 4A 4H. Effect of hyperosmotic shock on labeling 
efficiency: FIG. 4A, FIG. 4C, FIG. 4E, FIG. 4G: pHEN2.thy: 
FIG. 4B, FIG. 4D, FIG. 4F, FIG. 4H pHEN2.dig: FIGS. 4A 
and FIG. 4B, 1XPBS: FIG. 4C and FIG. 4D, 2.5XPBS: FIG. 
4E and FIG. 4F 5xPBS: FIG. 4G and FIG. 4H 10XPBS. 
FIGS. 5A-5D. Maximizing periplasmic FACS signal in 
ABLETMC labeled in 5xPBS using P. vector and superin 
fection with M13KO7 (moi of 10) 0.5 h pre-induction: FIG. 
5A pHEN.thy; FIG. 5C pHEN2.thy/M13K07: pHEN2.dig: 
FIG.5D pHEN2.dig/M13K07. 
FIGS. 6A-6C. FIG. 6A: Phage eluate titers, after each 
round of panning. FIG. 6B: Polyclonal phage ELISA of 
purified phage stocks on digoxin-ovalbumin. FIG. 6C: FAC 
Scanning naive library FIGS. 6C-1 and rounds one to five 
(FIGS. 6C-2 to FIGS. 6C-6) of panning on digoxin-BSA 
using BODIPYTM-digoxygenin. 
FIGS. 7A, 7B. Amino acid and nucleotide sequences of 
ScFV antibody fragments isolated by expression in the peri 
plasm and FACS. FIG. 7A: Heavy chain of digl is shown in 
true font while dig3 is shown in italics underneath. The 
nucleotide sequences corresponding to the heavy chains of 
dig1 and dig 3 are given by SEQ ID NO:17 and SEQ ID 
NO:18, respectively. Dig.2 variation from dig 1 is as indi 
cated in underlined text within CDR3. FIG. 7B: Light chain 
of dig1, 2 and 3 with variations in CDR3 indicated as for 
heavy chain. The nucleotide sequences corresponding to the 
light chains of dig1 and dig 3 are given by SEQID NO:19 
and SEQ ID NO:20, respectively. The underlined four 
nucleotide variation beginning at nucleotide 99 is given by 
SEQ ID NO. 21. 
FIGS. 8A-8D. Labeling of periplasmic scFv by fluores 
cently tagged oligonucleotide probe. ABLETMC cells 
expressing periplasmic sclv specific for either atrazine as a 
negative control (FIG. 8A and FIG. 8C) or for digoxin (FIG. 
8B and FIG. 8D) were labeled either with: 100 nM with 
digoxigenin-BODIPYTM (FIG. 8A and FIG. 8B) or 100 nM 
of dig-5A-FL (FIG. 8C and FIG. 8D). 10,000 events were 
recorded using a FACSort flow cytometer at a rate of 
approximately 1,000 events per second. 
FIGS. 9A 9B. Fluorescence discrimination of E. coli 
expressing the enzyme cutinase (an esterase) from control 
bacteria not expressing the enzyme. E. coli DH5a cells were 
transformed either with the plasmid pPAD18 Cm (control 
cells) or with the derivative plasmid pKG3-53-1 encoding 
the Fusarium solani enzyme cutinase. FIG. 9A. Fluores 
cence histogram showing the selective labeling of E. coli 
expressing cutinase in the periplasm (pkg3-53-1 containing 
cells) using a fluorescent esterase substrate (10 uM Fluo 
rescein Dibutyrate) for 30 minutes at 37° C. FIG. 9B. 
Fluorescence histogram of from selective labeling of culti 
nase-expressing cells (transcribed from the pKG3-53-4 vec 
tor) labeled with a fluorescent pH-Sensitive Dye (1 uM 
LysoSensor Green DND-189) in the presence of cutinase 













labeled for 5 minutes at 25°C. Acidification of the periplasm 
occurred as a result of ester hydrolysis by the cutinase. 
DESCRIPTION OF ILLUSTRATIVE 
EMBODIMENTS 
The present technology circumvents the limitations of the 
prior art and provides an entirely novel means for the 
screening of very large polypeptide libraries. In particular, 
the invention overcomes deficiencies in the prior art by 
providing a rapid approach for isolating proteins that bind to 
small molecules and peptides via “display-less' library 
screening. A description of an example of Such a process in 
accordance with the invention is described for illustrative 
purposes in FIG. 1. In the technique, libraries of candidate 
binding proteins. Such as antibody sequences, are expressed 
in soluble form in the periplasmic space of gram negative 
bacteria, such as Escherichia coli, and are mixed with a 
labeled ligand. The periplasm comprises the space defined 
by the inner and outer membranes of a gram-negative 
bacterium. 
In wild-type E. coli and other gram negative bacteria, the 
outer membrane serves as a permeability barrier that 
severely restricts the diffusion of molecules greater than 600 
Da into the periplasmic space (Decad and Nikado, 1976). 
Conditions that increase the permeability of the outer mem 
brane, allowing larger molecules to diffuse in the periplasm, 
have two deleterious effects in terms of the ability to screen 
libraries: (a) the cell viability is affected to a significant 
degree and (b) the diffusion of molecules into the cell is 
accompanied by the diffusion of proteins and other macro 
molecules. The expressed proteins leak out of the periplasm 
and thus the resulting cell based libraries cannot be screened 
in a meaningful way. However, the inventors have identified 
experimental conditions such that allow fluorescent conju 
gates of ligands and polypeptides equilibrate across the outer 
membrane while proteins secreted into the periplasm remain 
within the cell. Therefore, in bacterial cells expressing 
recombinant polypeptides with affinity for the ligand, the 
concentration of the labeled ligand bound to the binding 
protein is increased, allowing the bacteria to be isolated from 
the rest of the library. Where fluorescent labeling of the 
target ligand is used, cells may efficiently be isolated by 
fluorescence activated cell sorting (FACS). Thus, in effect, 
the cell envelope serves as a “dialysis bag” that retains 
macromolecule:ligand complexes, but not free ligand (FIG. 
1). With this approach, existing libraries of secreted proteins 
in bacteria can be easily tested for ligand binding without the 
need for Subcloning into a phage or cell Surface display 
system. 
I. ANCHOR-LESS DISPLAY LIBRARY 
SCREENING 
Prior art methods of both phage display and bacterial cell 
surface display suffer from a limitation in that the protein is 
required, by definition, to be physically displayed on the 
surface of the vehicle used, to allow unlimited access to the 
targets (immobilized for phage or fluorescently conjugated 
ligands for FACS) (U.S. Pat. No. 5,223,409, the disclosure 
of which is specifically incorporated herein by reference in 
its entirety). Certain proteins are known to be poorly dis 
played on phage (Maenaka et al., 1996; Corey et al., 1993) 
and the toxic effects of cell surface display have been treated 
at length (Daugherty et al., 1999). The proteins to be 
displayed also need to be expressed as fusion proteins, 
which may alter their function. The selection constraints 
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imposed by any display system may, therefore, limit the 
application to relatively small and 'simple proteins and 
deny access to a multitude of large and complex multisub 
unit species. The latter are very likely to be incapable of 
partaking efficiently in the complex process of phage assem 
bly termination or outer-membrane translocation without 
very serious effects on host cell viability. 
Herein, the inventors have described conditions whereby 
expressed binding proteins, for example, an antibody, are 
targeted to the periplasmic compartment of E. coli and yet 
are amenable to binding ligands and peptides of up to at least 
2 kDa. As used herein, the term “binding protein’ includes 
not only antibodies, but also fragments of antibodies, as well 
as any other polypeptide or protein potentially capable of 
binding a given target molecule. The antibody or other 
binding proteins may be expressed with the invention 
directly and not as fusion proteins Such a technique may be 
termed “anchor-less-display” (ALD). To understand how it 
may work, one needs to be aware of the location in which 
it functions. 
The periplasmic compartment is contained between the 
inner and outer membranes of Gram negative cells (see, e.g., 
Oliver, 1996). As a sub-cellular compartment, it is subject to 
variations in size, shape and content that accompany the 
growth and division of the cell. Within a framework of 
peptidoglycan heteroploymer is a dense mileau of periplas 
mic proteins and little water, lending a gel-like consistency 
to the compartment (Hobot et al., 1984; Van Wielink and 
Duine, 1990). The peptidoglycan is polymerized to different 
extents depending on the proximity to the outer membrane, 
close-up it forms the murein sacculus that affords cell shape 
and resistance to osmotic lysis. 
The outer membrane (see Nikaido, 1996) is composed of 
phospholipids, porin proteins and, extending into the 
medium, lipopolysaccharide (LPS). The molecular basis of 
outer membrane integrity resides with LPS ability to bind 
divalent cations (Mg2+ and Ca2+) and link each other 
electrostatically to form a highly ordered quasi-crystalline 
ordered “tiled roof on the surface (Labischinski et al., 
1985). The membrane forms a very strict permeability 
barrier of allowing passage of molecules no greater than 
around 650 Da (Burman et al., 1972; Decad and Nikaido, 
1976) via the porins. The large water filled porin channels 
are primarily responsible for allowing free passage of mono 
and disaccharides, ions and amino acids in to the periplasm 
compartment (Naeke, 1976: Nikaido and Nakae, 1979; 
Nikaido and Vaara, 1985). With such strict physiological 
regulation of access by molecules to the periplasm it may 
appear, at first glance, inconceivable that ALD should work 
unless the ligands employed are at or below the 650 Da 
exclusion limit or are analogues of normally permeant 
compounds. However, the inventors have shown that ligands 
at least 2000 Da in size can diffuse into the periplasm. Such 
diffusion can be aided by one or more treatments of a 
bacterial cell, thereby rendering the outer membrane more 
permeable, as is described herein below. 
II. LIGAND ACCESS TO THE BACTERIAL 
PERIPLASM 
Certain classes of hydrophobic antibiotics, larger than the 
650 Da exclusion limit, can diffuse through the bacterial 
outer membrane itself, independent of membrane porins 
(Farmer et al., 1999). The process may actually permeabilize 
the membrane on so doing (Jouenne and Junter, 1990). Such 













periplasmic loops of a cytoplasmic membrane protein in 
vivo with a polymyxin B nonapeptide (Wada et al., 1999). 
Also, certain long chain phosphate polymers (100 Pi) appear 
to bypass the normal molecular sieving activity of the outer 
membrane altogether (Rao and Torriani, 1988). However, 
Such conditions generally lead to a decrease in cell viability. 
Maintaining the cells in a viable state is essential for library 
screening applications since non-viable cells cannot be 
propagated. 
The inventors have defined conditions that lead to the 
permeation of ligands into the periplasm without loss of 
viability or release of the expressed proteins from the cells. 
As a result, cells expressing binding protein can be fluores 
cently labeled simply by incubating with a solution of 
fluorescently labeled ligand. The inventors have observed 
marked differences in labeling efficiencies of different 
strains of bacterial host cells. It has been shown previously 
that increased permeability due to Ompl overexpression 
was caused by the absence of a histone like protein resulting 
in a decrease in the amount of a negative regulatory mRNA 
for OmpF translation (Painbeni et al., 1997). Also, DNA 
replication and chromosomal segregation is known to rely 
on intimate contact of the replisome with the inner mem 
brane, which itself contacts the outer membrane at numerous 
points. That the FACS optimal ABLEC strain has mutations 
altering plasmid copy number is thus, noteworthy. 
The inventors also noticed that treatments such as hyper 
osmotic shock can improve labeling significantly. It is 
known that many agents including, calcium ions (Bukau et 
al., 1985) and even Tris buffer (Irvin et al., 1981) alter the 
permeability of the outer-membrane. Further, the inventors 
found that phage infection stimulates the labeling process. 
Both the filamentous phage inner membrane protein pII and 
the large multimeric outer membrane protein plV can alter 
membrane permeability (Boeke et al., 1982) with mutants in 
pIV known to improve access to maltodextrins normally 
excluded (Marciano et al., 1999). Using the techniques of 
the invention comprising a judicious combination of strain, 
salt and phage, the inventors Surpassed the highest fluores 
cent signal reported even for cell Surface display of the 
antidigoxin antibody scFv (Daugherty et al., 1999). This 
result demonstrated that the anchor-less display methodol 
ogy allows for excellent ligand-dependent labeling of cells. 
Cells labeled with a fluorescent ligand can then be easily 
isolated from cells that express non-binding protein mutants 
using flow cytometry or other related techniques. 
III. PERIPLASMIC PEPTIDE EXPRESSION 
In one embodiment of the invention, bacterial cells are 
provided expressing candidate molecules in the periplasm of 
the bacteria. An advantage of the instant invention is that, 
unlike prior art phage display techniques, it is not necessary 
that the candidate molecule be surface-bound, thereby lim 
iting the potential for effects due to surface interactions with 
the candidate molecule, or limitations in the expression 
thereof. Thus, the invention employs “anchor-less display.” 
The general scheme behind the technique of the invention is 
the advantageous expression of a heterogeneous collection 
of peptides in soluble form in the periplasm. 
Methods that may be employed with the current invention 
for the expression of heterologous proteins in the periplasm 
of Gram negative bacteria are well known in the art (see, for 
example, U.S. Pat. Nos. 5,646,015 and 5,759,810, the dis 
closures of which are incorporated herein by reference in 
their entirety). In Such techniques, bacterial-encoded heter 
ologous proteins can be directed across the inner membrane 
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of the bacterial cell envelope, into the space between the 
inner and the outer membrane known as the periplasm. For 
example, when a protein is expressed as a fusion protein 
having an E. coli-recognized peptide or 'signal peptide' 
attached to its N-terminus, the desired protein is secreted 
into the periplasm. Signal peptides that could potentially be 
employed with the invention are well known in the art and 
include, for example, those described by Watson (1984), 
Oka et al. (1985), Hsiung et al., (1986) and EP 177.343, each 
of the disclosures of which are specifically incorporated 
herein by reference in their entirety. 
In phage display, a gene encoding a protein of interest is 
commonly linked to the amino-terminal domain of the gene 
III coat protein of the filamentous phage M13, or another 
Surface-associated molecule. The fusion is mutated to form 
a library of structurally related fusion proteins that are 
expressed in low quantity on the Surface of phagemid 
candidates. For example, U.S. Pat. No. 5,571,698 describes 
directed evolution using an M13 phagemid system. How 
ever, in the instant invention, fusion to the gene III coat 
protein is not necessary, as the protein is expressed in 
soluble form in the periplasm. Instead, it may be desirable to 
create a fusion protein of the candidate periplasmic-ex 
pressed binding protein or antibody with a signal sequence 
directing expression of that protein in the periplasm. As 
Such, techniques for the creation of heterogeneous collec 
tions of candidate molecules, well known to those of skill in 
the art in conjunction with phage display, could be adapted 
for use with the invention. Those of skill in the art will 
recognize that such adaptations will include the use of 
bacterial elements for expression and secretion of candidate 
molecules into the periplasm, including, promoter, enhanc 
ers or leader sequences. The current invention provides the 
advantage relative to phage display of not requiring the 
creation of fusions with Surface-associated molecules, as 
required in standard display protocols, which may be poorly 
expressed or may be deleterious to the host cell. 
Examples of techniques that could be employed in con 
junction with the invention for expression of candidate 
binding proteins and/or antibodies in the periplasm include 
the techniques for expression of immunoglobulin heavy 
chain libraries described in U.S. Pat. No. 5,824,520. In this 
technique, a single chain antibody library is generated by 
creating highly divergent, synthetic hyperVariable regions. 
Similar techniques for antibody display are given by U.S. 
Pat. No. 5,922,545. 
In accordance with another embodiment of the invention, 
the identification and selection of novel substrates for 
enzymes also could be carried out in the bacterial periplasm 
(see, for example, U.S. Pat. No. 5,780.279). The method 
comprises constructing a gene fusion comprising DNA 
encoding a polypeptide fused to a DNA encoding a substrate 
peptide. The DNA encoding the substrate peptide is mutated 
at one or more codons, thereby generating a family of 
mutants. The fusion protein could be expressed in the 
periplasm of a bacterium and Subjected to potential inhibi 
tion or modification by target ligands. Those bacteria in 
which modifications have taken place can then be separated 
from those that have not. By employing FACS screening 
technology, the general progress of a reaction could simi 
larly be efficiently monitored. 
IV. SCREENING CANDIDATE MOLECULES 
The present invention further comprises methods for 
identifying molecules capable of binding a target ligand. The 













candidate Substances, or, alternatively, may comprise par 
ticular classes of compounds selected with an eye towards 
structural attributes that are believed to make them more 
likely to bind the target ligand. In a preferred embodiment of 
the invention, the candidate molecule is an antibody, or a 
fragment or portion thereof. In other embodiments of the 
invention, the candidate molecule may be another binding 
protein or an enzyme. 
To identify a candidate molecule capable of binding a 
target ligand in accordance with the invention, one may 
carry out the steps of providing a population of Gram 
negative bacterial cells comprising candidate molecules 
expressed in the periplasm of the bacteria; admixing the 
bacteria and at least a first labeled target ligand capable of 
diffusing into the periplasm of the bacteria; and identifying 
at least a first bacterium expressing a molecule capable of 
binding the target ligand. 
In the aforementioned method, the binding between the 
candidate molecule and the ligand will prevent the diffusing 
out of the cell. In this way, multiple molecules of the labeled 
ligand will be retained in the periplasm of the bacterium. The 
labeling may then be used to isolate the cell expressing the 
molecule capable of binding the target ligand, and in this 
way, the gene encoding the molecule isolated. The molecule 
capable of binding the target ligand may then be produced 
in large quantities using in vivo or ex vivo expression 
methods, and then used for any desired application, for 
example, for diagnostic or therapeutic applications, as 
described below. 
As used herein the term “candidate molecule' or “candi 
date polypeptide' refers to any molecule or polypeptide that 
may potentially have affinity for a target ligand. The candi 
date Substance may be a protein or fragment thereof, includ 
ing a small molecule. The candidate molecule may in one 
embodiment of the invention, comprise an antibody 
sequence or fragment thereof. Such sequences may be 
particularly designed for the likelihood that they will bind a 
target ligand. 
Binding proteins or antibodies isolated in accordance with 
the invention also may help ascertain the structure of a target 
ligand. In principle, this approach yields a pharmacore upon 
which Subsequent drug design can be based. It is possible to 
bypass protein crystallography altogether by generating 
anti-idiotypic antibodies to a functional, pharmacologically 
active antibody. As a mirror image of a mirror image, the 
binding site of anti-idiotype would be expected to be an 
analog of the original antigen. The anti-idiotype could then 
be used to identify and isolate peptides from banks of 
chemically- or biologically-produced peptides. Selected 
peptides would then serve as the pharmacore. Anti-idiotypes 
may be generated using the methods described herein for 
producing antibodies, using an antibody as the antigen. 
On the other hand, one may simply acquire, from various 
commercial sources, Small molecule libraries that are 
believed to meet the basic criteria for binding the target 
ligand. Such libraries could be provided by way of nucleic 
acids encoding the Small molecules or bacteria expressing 
the molecules. 
V. SCREENING OF ENZYME LIBRARIES 
Yet another aspect of the present invention relates to the 
isolation of enzyme catalysts capable of catalyzing the 
conversion of a reaction Substrate to a product. The inven 
tors have discovered that a number of fluorescent substrates 
for enzymatic reactions can permeate into the periplasmic 
space of E. coli. Cells that express an enzyme capable of 
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reacting with Such a substrates produce fluorescent products 
in direct proportion to the catalytic activity of the protein. 
The inventors have further found that the fluorescent product 
of the enzymatic reaction is retained within the cell. As a 
result, cells become fluorescently stained in proportion to 
the catalytic activity of the expressed enzyme and can be 
sorted from a population of mutant proteins by FACS. 
Flow cytometry is well suited for the analysis of enzyme 
activity and kinetics at the single cell level. The inventors 
have discovered that many fluorescent substrates that nor 
mally cannot permeate into the cytoplasm can nonetheless 
freely diffuse into the periplasm of bacterial cells. Cells 
expressing an enzyme in the bacterial periplasm are thus 
capable of converting the substrate into the respective fluo 
rescent product. The inventors further discovered, unexpect 
edly, that following the enzymatic reaction the fluorescent 
product is selectively retained within the periplasm and thus 
the cell becomes fluorescent and can be isolated by FACS. 
In the case of the LysoSensor Green DND-189 in the 
presence of 1 mM 4-nitrophenylbutyrate reaction, it is not 
a fluorescent product that is being detected. Rather, the 
LysoSensor Green DND-189 is a pH-sensitive dye, and as 
the enzyme catalyzes the conversion of 4-nitrophenyl 
butyrate to 4-nitrophenol and butyric acid in the periplasm, 
the pH drops in unbuffered solution. This drop in pH is being 
detected as increased fluorescence by the LysoSensor Green 
DND-189, which remains associated with the cell via elec 
trostatic attraction. Here, the LysoSensor Green DND-189 
becomes protonated at lower pH and thus positively 
charged, so it associates with the negatively-charged bacte 
rial outer membrane long enough to allow FACS isolation. 
1. Cloning of Binding Protein Coding Sequences 
The binding affinity of an antibody or another binding 
protein can, for example, be determined by the Scatchard 
analysis of Munson & Pollard (1980). After a bacterial cell 
is identified that produces molecules of the desired speci 
ficity, affinity, and/or activity, the corresponding coding 
sequence may be cloned. In this manner, DNA encoding the 
molecule can be isolated and sequenced using conventional 
procedures (e.g., by using oligonucleotide probes that are 
capable of binding specifically to genes encoding the anti 
body or binding protein). 
Once isolated, the antibody or binding protein DNA may 
be placed into expression vectors, which can then trans 
fected into host cells such as simian COS cells, Chinese 
hamster ovary (CHO) cells, or myeloma cells that do not 
otherwise produce immunoglobulin protein, to obtain the 
synthesis of binding protein in the recombinant host cells. 
The DNA also may be modified, for example, by substitut 
ing the coding sequence for human heavy and light chain 
constant domains in place of the homologous murine 
sequences (Morrison, et al., 1984), or by covalently joining 
to the immunoglobulin coding sequence all or part of the 
coding sequence for a non-immunoglobulin polypeptide. In 
that manner, "chimeric' or “hybrid binding proteins are 
prepared that have the desired binding specificity. 
Typically, Such non-immunoglobulin polypeptides are 
substituted for the constant domains of an antibody, or they 
are substituted for the variable domains of one antigen 
combining site of an antibody to create a chimeric bivalent 
antibody comprising one antigen-combining site having 
specificity the target ligand and another antigen-combining 
site having specificity for a different antigen. 
Chimeric or hybrid antibodies also may be prepared in 
vitro using known methods in synthetic protein chemistry, 
including those involving crosslinking agents. For example, 













exchange reaction or by forming a thioether bond. Examples 
of Suitable reagents for this purpose include iminothiolate 
and methyl-4-mercaptobutyrimidate. 
2. Maximization of Protein Affinity for Ligands 
In a natural immune response, antibody genes accumulate 
mutations at a high rate (somatic hypermutation). Some of 
the changes introduced will confer higher affinity, and B 
cells displaying high-affinity Surface immunoglobulin. This 
natural process can be mimicked by employing the tech 
nique known as “chain shuffling” (Marks et al., 1992). In 
this method, the affinity of “primary' human antibodies 
obtained in accordance with the invention could be 
improved by sequentially replacing the heavy and light 
chain V region genes with repertoires of naturally occurring 
variants (repertoires) of V domain genes obtained from 
unimmunized donors. This technique allows the production 
of antibodies and antibody fragments with affinities in the 
nM range. A strategy for making very large antibody rep 
ertoires was described by Waterhouse et al., (1993), and the 
isolation of a high affinity human antibody directly from 
such large phage library was reported by Griffith et al., 
(1994). Gene shuffling also can be used to derive human 
antibodies from rodent antibodies, where the human anti 
body has similar affinities and specificities to the starting 
rodent antibody. According to this method, which is also 
referred to as "epitope imprinting, the heavy or light chain 
V domain gene of rodent antibodies obtained by the phage 
display technique is replaced with a repertoire of human V 
domain genes, creating rodent-human chimeras. Selection 
on the antigen results in isolation of human variable regions 
capable of restoring a functional antigen-binding site, i.e. the 
epitope governs (imprints) the choice of partner. When the 
process is repeated in order to replace the remaining rodent 
V domain, a human antibody is obtained (see PCT patent 
application WO 93/06213, published Apr. 1, 1993). Unlike 
traditional humanization of rodent antibodies by CDR graft 
ing, this technique provides completely human antibodies, 
which have no framework or CDR residues of rodent origin. 
3. Labeled Ligands 
In one embodiment of the invention, an antibody or 
binding protein is isolated which has affinity for a labeled 
ligand. Such a labeled ligand is, in one embodiment of the 
invention, preferably less that 50,000 Da in size in order to 
allow efficient diffusion of the ligand into the bacterial 
periplasm. As indicated above, it will typically be desired in 
accordance with the invention to provide a ligand which has 
been labeled with one or more detectable agent(s). This can 
be carried out, for example, by linking the ligand to at least 
one detectable agent to form a conjugate. For example, it is 
conventional to link or covalently bind or complex at least 
one detectable molecule or moiety. A "label' or “detectable 
label' is a compound and/or element that can be detected 
due to specific functional properties, and/or chemical char 
acteristics, the use of which allows the ligand to which it is 
attached to be detected, and/or further quantified if desired. 
Examples of labels which could be used with the invention 
include, but are not limited to, enzymes, radiolabels, hap 
tens, fluorescent labels, phosphorescent molecules, chemi 
luminescent molecules, chromophores, luminescent mol 
ecules, photoaffinity molecules, colored particles or ligands, 
Such as biotin. 
In a preferred embodiment of the invention, a visually 
detectable marker is used such that automated Screening of 
cells for the label can be carried out. In particular, fluores 
cent labels are preferred in that they allow use of FACS for 
isolation of cells expressing a desired binding protein or 
antibody. Examples of agents that may be detected by 
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visualization with an appropriate instrument are known in 
the art, as are methods for their attachment to a desired 
ligand (see, e.g., U.S. Pat. Nos. 5,021,236: 4,938,948; and 
4,472,509, each incorporated herein by reference). Such 
agents can include paramagnetic ions; radioactive isotopes; 
fluorochromes; NMR-detectable substances and substances 
for X-ray imaging. Types of fluorescent labels that may be 
used with the invention will be well known to those of skill 
in the art and include, for example, Alexa 350, Alexa 430, 
AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY 
FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cas 
cade Blue, Cy3, Cy5,6-FAM, Fluorescein Isothiocyanate, 
HEX, 6-JOE, Oregon Green 488, Oregon Green 500, 
Oregon Green 514, Pacific Blue, REG, Rhodamine Green, 
Rhodamine Red, Renographin, ROX, TAMRA, TET. Tet 
ramethylrhodamine, and/or Texas Red. 
Examples of paramagnetic ions that could be used as 
labels include ions such as chromium (III), manganese (II), 
iron (III), iron (II), cobalt (II), nickel (II), copper (II), 
neodymium (III), Samarium (III), ytterbium (III), gado 
linium (III), vanadium (II), terbium (III), dysprosium (III), 
holmium (III) and/or erbium (III). Ions useful in other 
contexts include but are not limited to lanthanum (III), gold 
(III), lead (II), and especially bismuth (III). 
Another type of ligand conjugates contemplated in the 
present invention are those where the ligand is linked to a 
secondary binding molecule and/or to an enzyme (an 
enzyme tag) that will generate a colored product upon 
contact with a chromogenic Substrate. Examples of Such 
enzymes include urease, alkaline phosphatase, (horseradish) 
hydrogen peroxidase or glucose oxidase. In Such instances, 
it will be desired that cells selected remain viable. Preferred 
secondary binding ligands are biotin and/or avidin and 
streptavidin compounds. The use of such labels is well 
known to those of skill in the art and are described, for 
example, in U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 
3.996,345; 4,277,437; 4,275,149 and 4,366,241; each incor 
porated herein by reference. 
Molecules containing azido groups also may be used to 
form covalent bonds to proteins through reactive nitrene 
intermediates that are generated by low intensity ultraviolet 
light (Potter & Haley, 1983). In particular, 2- and 8-azido 
analogues of purine nucleotides have been used as site 
directed photoprobes to identify nucleotide-binding proteins 
in crude cell extracts (Owens & Haley, 1987; Atherton et al., 
1985). The 2- and 8-azido nucleotides have also been used 
to map nucleotide-binding domains of purified proteins 
(Khatoon et al., 1989: King et al., 1989; and Dholakia et al., 
1989) and may be used as ligand binding agents. 
Labeling can be carried out by any of the techniques well 
known to those of skill in the art. For instance, ligands can 
be labeled by contacting the ligand with the desired label and 
a chemical oxidizing agent such as sodium hypochlorite, or 
an enzymatic oxidizing agent, such as lactoperoxidase. 
Similarly, a ligand exchange process could be used. Alter 
natively, direct labeling techniques may be used, e.g., by 
incubating the label, a reducing agent such as SNC1, a 
buffer solution Such as sodium-potassium phthalate solution, 
and the ligand. Intermediary functional groups on the ligand 
could also be used, for example, to bind labels to a ligand in 
the presence of diethylenetriaminepentaacetic acid (DTPA) 
or ethylene diaminetetracetic acid (EDTA). 
Other methods are also known in the art for the attach 
ment or conjugation of a ligand to its conjugate moiety. 
Some attachment methods involve the use of an organic 
chelating agent Such a diethylenetriaminepentaacetic acid 













N-chloro-p-toluenesulfonamide; and/or tetrachloro-3C.-6C.- 
diphenylglycouril-3 attached to the ligand (U.S. Pat. Nos. 
4,472,509 and 4.938,948, each incorporated herein by ref 
erence). Ligands also may be reacted with an enzyme in the 
presence of a coupling agent such as glutaraldehyde or 
periodate. Conjugates with fluorescein markers can be pre 
pared in the presence of these coupling agents or by reaction 
with an isothiocyanate. In U.S. Pat. No. 4,938,948, imaging 
of breast tumors is achieved using monoclonal antibodies 
and the detectable imaging moieties are bound to the anti 
body using linkers such as methyl-p-hydroxybenzimidate or 
N-Succinimidyl-3-(4-hydroxyphenyl)propionate. 
V. ILLUSTRATIVE USE OF THE INVENTION 
The examples described herein demonstrate the use of the 
invention for the affinity maturation of the anti-cardiac 
glycoside schv 26.10, and the de novo isolation of antibod 
ies from large repertoire libraries. Importantly the current 
invention results in the isolation of protein variants that are 
missed by other protein library screening technologies Such 
as phage display. As discussed above, most sclv are toxic to 
the host cell when targeted to the periplasm. Although 
reasonable expression levels of Such molecules may be 
obtained by altering culture conditions, provision of chap 
erones and foldases etc., the host cells are often not recov 
erable after expression. FACS selection with the anchor 
less-display (ALD) techniques of the invention requires a 
high enough expression level for a strong FACS signal but 
not so high as to irreversibly damage the cell and prevent its 
isolation. In contrast, phage display imposes little selection 
for expression. As a result, proteins isolated from a phage 
display library screening program are often very difficult to 
produce in Sufficient quantities for further characterization. 
The advent of highly expressable framework-based libraries 
(Knappicket al., 2000) should help circumvent the expres 
sion versus viability problem. The high sort-rates of current 
FACS machines generally enable the screening of very large 
libraries (10° 10') and can completely circumvent phage or 
cell Surface display. 
The ability to specifically label periplasmic expressed 
proteins with appropriate fluorescent ligands also has appli 
cations other than library screening. Specifically labeling 
with fluorescent ligands and flow cytometry can be used for 
monitoring production during protein manufacturing. While 
flow cytometry has been used previously for the analysis of 
bacterial cells, it has not been used for the specific labeling 
and quantitation of periplasmic proteins. However, a large 
number of commercially important proteins including IGF-1 
several interleukins, enzymes such as urokinase-type plas 
minogen activator, antibody fragments, inhibitors (e.g., 
Bovine pancreatic trypsin inhibitor) are expressed in recom 
binant bacteria in a form secreted into the periplasmic space 
The level of production of such proteins within each cell in 
a culture can be monitored by utilizing an appropriate 
fluorescent ligand and flow cytometric analysis, according to 
the techniques taught by the present invention. 
Generally, monitoring protein expression requires cell 
lysis and detection of the protein by immunological tech 
niques or following chromatographic separation. However, 
ELISA or western blot analysis is time-consuming and does 
not provide information on the distribution of expression 
among a cell population and cannot be used for on-line 
monitoring (Thorstenson et al., 1997: Berrier et al., 2000). In 
contrast, FACS labeling is rapid and simple and can well be 
applied to online monitoring of industrial size fermentations 
of recombinant proteins expressed in gram-negative bacte 
US 7,083,945 B1 
17 
ria. Similarly, the invention could be used to monitor the 
production of a particular byproduct of a biological reaction. 
This also could be used to measure the relative concentration 
or specific activity of an enzyme expressed in vivo in a 
bacterium or provided ex vivo. The passive and instant 
nature of ALD provides the advantage of allowing instant 
analysis of a population of cells with direct observations 
rather than relying on extensive indirect protocols. 
Once a ligand-binding protein, such as an antibody, has 
been isolated in accordance with the invention, it may be 
desired to link the molecule to at least one agent to form a 
conjugate to enhance the utility of that molecule. For 
example, in order to increase the efficacy of antibody 
molecules as diagnostic or therapeutic agents, it is conven 
tional to link or covalently bind or complex at least one 
desired molecule or moiety. Such a molecule or moiety may 
be, but is not limited to, at least one effector or reporter 
molecule. Effector molecules comprise molecules having a 
desired activity, e.g., cytotoxic activity. Non-limiting 
examples of effector molecules which have been attached to 
antibodies include toxins, anti-tumor agents, therapeutic 
enzymes, radio-labeled nucleotides, antiviral agents, chelat 
ing agents, cytokines, growth factors, and oligo- or poly 
nucleotides. By contrast, a reporter molecule is defined as 
any moiety which may be detected using an assay. Tech 
niques for labeling Such a molecule are known to those of 
skill in the art and have been described herein above. 
Labeled binding proteins such as antibodies which have 
been prepared in accordance with the invention may also 
then be employed, for example, in immunodetection meth 
ods for binding, purifying, removing, quantifying and/or 
otherwise generally detecting biological components such as 
protein(s), polypeptide(s) or peptide(s). Some immunode 
tection methods include enzyme linked immunosorbent 
assay (ELISA), radioimmunoassay (RIA), immunoradi 
ometric assay, fluoroimmunoassay, chemiluminescent assay, 
bioluminescent assay, and Western blot to mention a few. 
The steps of various useful immunodetection methods have 
been described in the Scientific literature, such as, e.g., 
Doolittle M H and Ben-Zeev O, 1999; Gulbis B and Galand 
P, 1993; and De Jager R et al., 1993, each incorporated 
herein by reference. Such techniques include binding assays 
Such as the various types of enzyme linked immunosorbent 
assays (ELISAS) and/or radioimmunoassays (RIA) known 
in the art. 
The ligand-binding molecules, including antibodies, pre 
pared in accordance with the present invention may also, for 
example, in conjunction with both fresh-frozen and/or for 
malin-fixed, paraffin-embedded tissue blocks prepared for 
study by immunohistochemistry (IHC). The method of pre 
paring tissue blocks from these particulate specimens has 
been successfully used in previous IHC studies of various 
prognostic factors, and/or is well known to those of skill in 
the art (Abbondanzo et al., 1990). 
VI. AUTOMATED SCREENING WITH FACS 
In one embodiment of the invention, fluorescence acti 
vated cell sorting (FACS) screening or other automated flow 
cytometric techniques may be used for the efficient isolation 
of a bacterial cell comprising a labeled ligand bound to a 
candidate molecule in the periplasm of the bacteria. Instru 
ments for carrying out FACS are known to those of skill in 
the art and are commercially available to the public. 
Examples of such instruments include FACS Star Plus, 













(Foster City, Calif.) Epics C from Coulter Epics Division 
(Hialeah, Fla.) and MoFlo from Cytomation (Colorado 
Springs, Co). 
Flow cytometric techniques in general involve the sepa 
ration of cells or other particles in a liquid sample. Typically, 
the purpose of flow cytometry is to analyze the separated 
particles for one or more characteristics thereof, for 
example, presence of a labeled ligand or other molecule. The 
basis steps of flow cytometry involve the direction of a fluid 
sample through an apparatus Such that a liquid stream passes 
through a sensing region. The particles should pass one at a 
time by the sensor and are categorized base on size, refrac 
tion, light scattering, opacity, roughness, shape, fluores 
Cence, etc. 
Rapid quantitative analysis of cells proves useful in 
biomedical research and medicine. Apparati permit quanti 
tative multiparameter analysis of cellular properties at rates 
of several thousand cells per second. These instruments 
provide the ability to differentiate among cell types. Data are 
often displayed in one-dimensional (histogram) or two 
dimensional (contour plot, scatter plot) frequency distribu 
tions of measured variables. The partitioning of multipa 
rameter data files involves consecutive use of the interactive 
one- or two-dimensional graphics programs. 
Quantitative analysis of multiparameter flow cytometric 
data for rapid cell detection consists of two stages: cell class 
characterization and sample processing. In general, the 
process of cell class characterization partitions the cell 
feature into cells of interest and not of interest. Then, in 
sample processing, each cell is classified in one of the two 
categories according to the region in which it falls. Analysis 
of the class of cells is very important, as high detection 
performance may be expected only if an appropriate char 
acteristic of the cells is obtained. 
Not only is cell analysis performed by flow cytometry, but 
so too is sorting of cells. In U.S. Pat. No. 3,826,364, an 
apparatus is disclosed which physically separates particles, 
Such as functionally different cell types. In this machine, a 
laser provides illumination which is focused on the stream of 
particles by a suitable lens or lens system so that there is 
highly localized scatter from the particles therein. In addi 
tion, high intensity source illumination is directed onto the 
stream of particles for the excitation of fluorescent particles 
in the stream. Certain particles in the stream may be selec 
tively charged and then separated by deflecting them into 
designated receptacles. A classic form of this separation is 
via fluorescent-tagged antibodies, which are used to mark 
one or more cell types for separation. 
Other methods for flow cytometry can be found in U.S. 
Pat. Nos. 4,284,412: 4,989,977; 4,498,766; 5,478,722: 
4,857,451; 4,774,189; 4,767,206; 4,714,682; 5,160,974; and 
4,661,913, each of the disclosures of which are specifically 
incorporated herein by reference. 
VII. NUCLEIC ACID-BASED EXPRESSION 
SYSTEMS 
Nucleic acid-based expression systems may find use, in 
certain embodiments of the invention, for the expression of 
recombinant proteins. For example, one embodiment of the 
invention involves transformation of Gram negative bacteria 
with the coding sequences of candidate antibody or other 
binding proteins having affinity for a selected ligand and the 
expression of Such candidate molecules in the periplasm of 
the Gram negative bacteria. In other embodiments of the 
invention, expression of Such coding sequences may be 
carried, for example, in eukaryotic host cells for the prepa 
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ration of isolated binding proteins having specificity for the 
target ligand. The isolated protein could then be used in one 
or more therapeutic or diagnostic applications. 
1. Methods of Nucleic Acid Delivery 
Certain aspects of the invention may comprise delivery of 
nucleic acids to target cells. For example, bacterial host cells 
may be transformed with nucleic acids encoding candidate 
molecules potentially capable binding a target ligand. In 
particular embodiments of the invention, it may be desired 
to target the expression to the periplasm of the bacteria. 
Transformation of eukaryotic host cells may similarly find 
use in the expression of various candidate molecules iden 
tified as capable of binding a target ligand. 
Suitable methods for nucleic acid delivery for transfor 
mation of a cell are believed to include virtually any method 
by which a nucleic acid (e.g., DNA) can be introduced into 
such a cell, or even an organelle thereof. Such methods 
include, but are not limited to, direct delivery of DNA such 
as by injection (U.S. Pat. Nos. 5,994,624, 5,981,274, 5,945, 
100, 5,780,448, 5,736,524, 5,702.932, 5,656,610, 5,589.466 
and 5,580,859, each incorporated herein by reference), 
including microinjection (Harlan and Weintraub, 1985; U.S. 
Pat. No. 5,789,215, incorporated herein by reference); by 
electroporation (U.S. Pat. No. 5,384.253, incorporated 
herein by reference); by calcium phosphate precipitation 
(Graham and Van Der Eb. 1973; Chen and Okayama, 1987: 
Rippe et al., 1990); by using DEAE-dextran followed by 
polyethylene glycol (Gopal, 1985); by direct sonic loading 
(Fechheimer et al., 1987); by liposome mediated transfec 
tion (Nicolau and Sene, 1982; Fraley et al., 1979; Nicolau et 
al., 1987; Wong et al., 1980: Kaneda et al., 1989: Kato et al. 
1991); by microprojectile bombardment (PCT Application 
Nos. WO94/09699 and 95/06128: U.S. Pat. Nos. 5,610,042: 
5,322,783 5,563,055, 5,550,318, 5,538,877 and 5,538,880, 
and each incorporated herein by reference); by agitation 
with silicon carbide fibers (Kaeppler et al., 1990; U.S. Pat. 
Nos. 5,302,523 and 5,464.765, each incorporated herein by 
reference); by Agrobacterium-mediated transformation 
(U.S. Pat. Nos. 5,591,616 and 5.563,055, each incorporated 
herein by reference); or by PEG-mediated transformation of 
protoplasts (Omirulleh et al., 1993; U.S. Pat. Nos. 4.684,611 
and 4,952,500, each incorporated herein by reference); by 
desiccation/inhibition-mediated DNA uptake (Potrykus et 
al., 1985). Through the application of techniques such as 
these, organelle(s), cell(s), tissue(s) or organism(s) may be 
stably or transiently transformed. 
a. Electroporation 
In certain embodiments of the present invention, a nucleic 
acid is introduced into a cell via electroporation. Electropo 
ration involves the exposure of a suspension of cells and 
DNA to a high-voltage electric discharge. In some variants 
of this method, certain cell wall-degrading enzymes, such as 
pectin-degrading enzymes, are employed to render the target 
recipient cells more susceptible to transformation by elec 
troporation than untreated cells (U.S. Pat. No. 5,384.253, 
incorporated herein by reference). Alternatively, recipient 
cells can be made more susceptible to transformation by 
mechanical wounding. 
b. Calcium Phosphate 
In other embodiments of the present invention, a nucleic 
acid is introduced to the cells using calcium phosphate 
precipitation. Human KB cells have been transfected with 
adenovirus 5 DNA (Graham and Van Der Eb, 1973) using 
this technique. Also in this manner, mouse L(A9), mouse 
C127, CHO, CV-1, BHK, NIH3T3 and HeLa cells were 














Okayama, 1987), and rat hepatocytes were transfected with 
a variety of marker genes (Rippe et al., 1990). 
2. Vectors 
Vectors may find use with the current invention, for 
example, in the transformation of a gram negative bacterium 
with a nucleic acid sequence encoding a candidate polypep 
tide which one wishes to screen for ability to bind a target 
ligand. In one embodiment of the invention, an entire 
heterogeneous “library of nucleic acid sequences encoding 
target polypeptides may be introduced into a population of 
bacteria, thereby allowing screening of the entire library. 
The term “vector” is used to refer to a carrier nucleic acid 
molecule into which a nucleic acid sequence can be inserted 
for introduction into a cell where it can be replicated. A 
nucleic acid sequence can be “exogenous,” which means 
that it is foreign to the cell into which the vector is being 
introduced or that the sequence is homologous to a sequence 
in the cell but in a position within the host cell nucleic acid 
in which the sequence is ordinarily not found. Vectors 
include plasmids, cosmids, viruses (bacteriophage, animal 
viruses, and plant viruses), and artificial chromosomes (e.g., 
YACs). One of skill in the art may construct a vector through 
standard recombinant techniques, which are described in 
Maniatis et al., 1988 and Ausubel et al., 1994, both of which 
references are incorporated herein by reference. 
The term "expression vector” refers to a vector containing 
a nucleic acid sequence coding for at least part of a gene 
product capable of being transcribed. In some cases, RNA 
molecules are then translated into a protein, polypeptide, or 
peptide. In other cases, these sequences are not translated, 
for example, in the production of antisense molecules or 
ribozymes. Expression vectors can contain a variety of 
“control sequences,” which refer to nucleic acid sequences 
necessary for the transcription and possibly translation of an 
operably linked coding sequence in a particular host organ 
ism. In addition to control sequences that govern transcrip 
tion and translation, vectors and expression vectors may 
contain nucleic acid sequences that serve other functions as 
well and are described infra. 
a. Promoters and Enhancers 
A "promoter” is a control sequence that is a region of a 
nucleic acid sequence at which initiation and rate of tran 
scription are controlled. It may contain genetic elements at 
which regulatory proteins and molecules may bind such as 
RNA polymerase and other transcription factors. The 
phrases "operatively positioned,” “operatively linked.” 
“under control.” and “under transcriptional control’ mean 
that a promoter is in a correct functional location and/or 
orientation in relation to a nucleic acid sequence to control 
transcriptional initiation and/or expression of that sequence. 
A promoter may or may not be used in conjunction with an 
"enhancer,” which refers to a cis-acting regulatory sequence 
involved in the transcriptional activation of a nucleic acid 
Sequence. 
A promoter may be one naturally associated with a gene 
or sequence, as may be obtained by isolating the 5' non 
coding sequences located upstream of the coding segment 
and/or exon. Such a promoter can be referred to as 'endog 
enous.” Similarly, an enhancer may be one naturally asso 
ciated with a nucleic acid sequence, located either down 
stream or upstream of that sequence. Alternatively, certain 
advantages will be gained by positioning the coding nucleic 
acid segment under the control of a recombinant or heter 
ologous promoter, which refers to a promoter that is not 
normally associated with a nucleic acid sequence in its 
natural environment. A recombinant or heterologous 
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enhancer refers also to an enhancer not normally associated 
with a nucleic acid sequence in its natural environment. 
Such promoters or enhancers may include promoters or 
enhancers of other genes, and promoters or enhancers iso 
lated from any other prokaryotic, viral, or eukaryotic cell, 
and promoters or enhancers not “naturally occurring, i.e., 
containing different elements of different transcriptional 
regulatory regions, and/or mutations that alter expression. In 
addition to producing nucleic acid sequences of promoters 
and enhancers synthetically, sequences may be produced 
using recombinant cloning and/or nucleic acid amplification 
technology, including PCRTM, in connection with the com 
positions disclosed herein (see U.S. Pat. No. 4,683.202, U.S. 
Pat. No. 5,928,906, each incorporated herein by reference). 
Furthermore, it is contemplated that the control sequences 
that direct transcription and/or expression of sequences 
within non-nuclear organelles such as mitochondria, chlo 
roplasts, and the like, can be employed as well. 
Naturally, it will be important to employ a promoter 
and/or enhancer that effectively directs the expression of the 
DNA segment in the cell type, organelle, and organism 
chosen for expression. One example of Such promoter that 
may be used with the invention is the E. coli arabinose 
promoter. Those of skill in the art of molecular biology 
generally are familiar with the use of promoters, enhancers, 
and cell type combinations for protein expression, for 
example, see Sambrook et al. (1989), incorporated herein by 
reference. The promoters employed may be constitutive, 
tissue-specific, inducible, and/or useful under the appropri 
ate conditions to direct high level expression of the intro 
duced DNA segment, Such as is advantageous in the large 
scale production of recombinant proteins and/or peptides. 
The promoter may be heterologous or endogenous. 
b. Initiation Signals and Internal Ribosome Binding Sites 
A specific initiation signal also may be required for 
efficient translation of coding sequences. These signals 
include the ATG initiation codon or adjacent sequences. 
Exogenous translational control signals, including the ATG 
initiation codon, may need to be provided. One of ordinary 
skill in the art would readily be capable of determining this 
and providing the necessary signals. It is well known that the 
initiation codon must be “in-frame' with the reading frame 
of the desired coding sequence to ensure translation of the 
entire insert. The exogenous translational control signals and 
initiation codons can be either natural or synthetic. The 
efficiency of expression may be enhanced by the inclusion of 
appropriate transcription enhancer elements. 
C. Multiple Cloning Sites 
Vectors can include a multiple cloning site (MCS), which 
is a nucleic acid region that contains multiple restriction 
enzyme sites, any of which can be used in conjunction with 
standard recombinant technology to digest the vector (see 
Carbonelli et al., 1999, Levenson et al., 1998, and Cocea, 
1997, incorporated herein by reference.) "Restriction 
enzyme digestion” refers to catalytic cleavage of a nucleic 
acid molecule with an enzyme that functions only at specific 
locations in a nucleic acid molecule. Many of these restric 
tion enzymes are commercially available. Use of Such 
enzymes is understood by those of skill in the art. Fre 
quently, a vector is linearized or fragmented using a restric 
tion enzyme that cuts within the MCS to enable exogenous 
sequences to be ligated to the vector. “Ligation” refers to the 
process of forming phosphodiester bonds between two 
nucleic acid fragments, which may or may not be contiguous 
with each other. Techniques involving restriction enzymes 
and ligation reactions are well known to those of skill in the 













d. Termination Signals 
The vectors or constructs of the present invention will 
generally comprise at least one termination signal. A “ter 
mination signal' or “terminator is comprised of the DNA 
sequences involved in specific termination of an RNA 
transcript by an RNA polymerase. Thus, in certain embodi 
ments, a termination signal that ends the production of an 
RNA transcript is contemplated. A terminator may be nec 
essary in vivo to achieve desirable message levels. 
Terminators contemplated for use in the invention include 
any known terminator of transcription described herein or 
known to one of ordinary skill in the art, including but not 
limited to, for example, rhp dependent or rho independent 
terminators. In certain embodiments, the termination signal 
may be a lack of transcribable or translatable sequence. Such 
as due to a sequence truncation. 
e. Origins of Replication 
In order to propagate a vector in a host cell, it may contain 
one or more origins of replication sites (often termed “ori' 
which is a specific nucleic acid sequence at which replica 
tion is initiated. Alternatively an autonomously replicating 
sequence (ARS) can be employed if the host cell is yeast. 
f. Selectable and Screenable Markers 
In certain embodiments of the invention, cells containing 
a nucleic acid construct of the present invention may be 
identified in vitro or in vivo by including a marker in the 
expression vector. Such markers would confer an identifi 
able change to the cell permitting easy identification of cells 
containing the expression vector. Generally, a selectable 
marker is one that confers a property that allows for selec 
tion. A positive selectable marker is one in which the 
presence of the marker allows for its selection, while a 
negative selectable marker is one in which its presence 
prevents its selection. An example of a positive selectable 
marker is a drug resistance marker. 
Usually the inclusion of a drug selection marker aids in 
the cloning and identification of transformants, for example, 
genes that confer resistance to neomycin, puromycin, hygro 
mycin, DHFR, GPT. Zeocin and histidinol are useful select 
able markers. In addition to markers conferring a phenotype 
that allows for the discrimination of transformants based on 
the implementation of conditions, other types of markers 
including screenable markers such as GFP, whose basis is 
calorimetric analysis, are also contemplated. Alternatively, 
screenable enzymes Such as herpes simplex virus thymidine 
kinase (tk) or chloramphenicol acetyltransferase (CAT) may 
be utilized. One of skill in the art would also know how to 
employ immunologic markers, possibly in conjunction with 
FACS analysis. The marker used is not believed to be 
important, so long as it is capable of being expressed 
simultaneously with the nucleic acid encoding a gene prod 
uct. Further examples of selectable and screenable markers 
are well known to one of skill in the art. 
3. Host Cells 
As used herein, the terms “cell,” “cell line,” and “cell 
culture' may be used interchangeably. All of these terms 
also include their progeny, which is any and all Subsequent 
generations. It is understood that all progeny may not be 
identical due to deliberate or inadvertent mutations. In the 
context of expressing a heterologous nucleic acid sequence, 
“host cell refers to a prokaryotic or eukaryotic cell, and it 
includes any transformable organism that is capable of 
replicating a vector and/or expressing a heterologous gene 
encoded by a vector. A host cell can, and has been, used as 
a recipient for vectors. A host cell may be “transfected' or 
“transformed, which refers to a process by which exog 
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enous nucleic acid is transferred or introduced into the host 
cell. A transformed cell includes the primary subject cell and 
its progeny. 
In particular embodiments of the invention, a host cell is 
a gram negative bacterial cell. These bacteria are Suited for 
use with the invention in that they posses a periplasmic 
space between the inner and outer membrane. As such, any 
other cell with Such a periplasmic space could be used in 
accordance with the invention. Examples of Gram negative 
bacteria that may find use with the invention may include, 
but are not limited to, E. coli, Pseudomonas aeruginosa, 
Vibrio cholera, Salmonella typhimurium, Shigella flexneri, 
Haemophilus influenza, Bordotella pertussi, Erwinia amy 
lovora, Rhizobium sp. The Gram negative bacterial cell may 
be still further defined as bacterial cell which has been 
transformed with the coding sequence of a candidate 
polypeptide capable of binding a selected ligand. The 
polypeptide will be expressed in the periplasmic space, and 
may comprise an antibody coding sequence or another 
sequence. One means for expression of the polypeptide in 
the periplasm is by attaching a leader sequence to the 
polypeptide capable of causing such directing. 
Numerous prokaryotic cell lines and cultures are available 
for use as a host cell, and they can be obtained through the 
American Type Culture Collection (ATCC), which is an 
organization that serves as an archive for living cultures and 
genetic materials (www.atcc.org). An appropriate host can 
be determined by one of skill in the art based on the vector 
backbone and the desired result. A plasmid or cosmid, for 
example, can be introduced into a prokaryote host cell for 
replication of many vectors. Bacterial cells used as host cells 
for vector replication and/or expression include DH5O. 
JM109, and KC8, as well as a number of commercially 
available bacterial hosts such as SURER) Competent Cells 
and SOLOPACKTM Gold Cells (STRATAGENETM, La Jolla). Alter 
natively, bacterial cells such as E. coli LE392 could be used 
as host cells for bacteriophage. 
Many host cells from various cell types and organisms are 
available and would be known to one of skill in the art. 
Similarly, a viral vector may be used in conjunction with 
either a eukaryotic or prokaryotic host cell, particularly one 
that is permissive for replication or expression of the vector. 
Some vectors may employ control sequences that allow it to 
be replicated and/or expressed in both prokaryotic and 
eukaryotic cells. One of skill in the art would further 
understand the conditions under which to incubate all of the 
above described host cells to maintain them and to permit 
replication of a vector. Also understood and known are 
techniques and conditions that would allow large-scale 
production of Vectors, as well as production of the nucleic 
acids encoded by vectors and their cognate polypeptides, 
proteins, or peptides. 
4. Expression Systems 
Numerous expression systems exist that comprise at least 
a part or all of the compositions discussed above. Such 
systems could be used, for example, for the production of a 
polypeptide product identified in accordance with the inven 
tion as capable of binding a particular ligand. Prokaryote 
and/or eukaryote-based systems can be employed for use 
with the present invention to produce nucleic acid 
sequences, or their cognate polypeptides, proteins and pep 
tides. Many such systems are commercially and widely 
available. 
Other examples of expression systems include 
STRATAGENER's COMPLETE CONTROLTM Inducible Mammalian 
Expression System, which involves a synthetic ecdysone 














expression system. Another example of an inducible expres 
sion system is available from INVITROGENTM, which carries 
the T-REXTM (tetracycline-regulated expression) System, an 
inducible mammalian expression system that uses the full 
length CMV promoter. INVITROGENR also provides a yeast 
expression system called the Pichia methanolica Expression 
System, which is designed for high-level production of 
recombinant proteins in the methylotrophic yeast Pichia 
methanolica. One of skill in the art would know how to 
express a vector, Such as an expression construct, to produce 
a nucleic acid sequence or its cognate polypeptide, protein, 
or peptide. 
5. Candidate Binding Proteins and Antibodies 
In certain aspects of the invention, candidate antibodies or 
other recombinant proteins potentially capable of binding a 
target ligand are expressed in the periplasm of a host 
bacterial cell. By expression of a heterogeneous population 
of such antibodies, those antibodies having a high affinity for 
a target ligand may be identified. The identified antibodies 
may then be used in various diagnostic or therapeutic 
applications, as described herein. 
As used herein, the term “antibody' is intended to refer 
broadly to any immunologic binding agent such as IgG, 
IgM, IgA, Ig) and IgE. The term “antibody' is also used to 
refer to any antibody-like molecule that has an antigen 
binding region, and includes antibody fragments such as 
Fab', Fab, F(ab'), single domain antibodies (DABs). Fv, 
Scfv (single chain FV), and engineering multivalent antibody 
fragments such as dibodies, tribodies and multibodies. The 
techniques for preparing and using various antibody-based 
constructs and fragments are well known in the art. Means 
for preparing and characterizing antibodies are also well 
known in the art (See, e.g., Antibodies: A Laboratory 
Manual, Cold Spring Harbor Laboratory, 1988; incorporated 
herein by reference). 
Once an antibody having affinity for a target ligand is 
identified, the antibody may be purified, if desired, using 
filtration, centrifugation and various chromatographic meth 
ods such as HPLC or affinity chromatography. Fragments of 
such antibodies can be obtained from the antibodies so 
produced by methods which include digestion with 
enzymes, such as pepsin or papain, and/or by cleavage of 
disulfide bonds by chemical reduction. Alternatively, anti 
body fragments encompassed by the present invention can 
be synthesized using an automated peptide synthesizer. 
A molecular cloning approach comprises one Suitable 
method for the generation of a heterogeneous population of 
candidate antibodies that may then be screened in accor 
dance with the invention for affinity to target ligands. In one 
embodiment of the invention, combinatorial immunoglobu 
lin phagemid can be prepared from RNA isolated from the 
spleen of an animal. By immunizing an animal with the 
ligand to be screened, the assay may be targeted to the 
particular antigen. The advantages of this approach over 
conventional techniques are that approximately 10 times as 
many antibodies can be produced and screened in a single 
round, and that new specificities are generated by H and L 
chain combination which further increases the chance of 
finding appropriate antibodies. 
VIII. MANIPULATION AND DETECTION OF 
NUCLEIC ACIDS 
In certain embodiments of the invention it may be desired 
to employ one or more techniques for the manipulation 
and/or detection of nucleic acids. Such techniques may 
include, for example, the preparation of vectors for trans 
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formation of host cells as well as methods for cloning 
selected nucleic acid segments from a transgenic cells. 
Methodology for carrying out Such manipulations will be 
well known to those of skill in the art in light of the instant 
disclosure. 5 
1. Amplification of Nucleic Acids 
Nucleic acids used as a template for amplification may be 
isolated from cells, tissues or other samples according to 
standard methodologies (Sambrook et al., 1989). In certain 
embodiments, analysis may be performed on whole cell or 10 
tissue homogenates or biological fluid samples without 
substantial purification of the template nucleic acid. The 
nucleic acid may be genomic DNA or fractionated or whole 
cell RNA. Where RNA is used, it may be desired to first 
convert the RNA to a complementary DNA. 15 
The term “primer, as used herein, is meant to encompass 
any nucleic acid that is capable of priming the synthesis of 
a nascent nucleic acid in a template-dependent process. 
Typically, primers are oligonucleotides from ten to twenty 
and/or thirty base pairs in length, but longer sequences can 20 
be employed. Primers may be provided in double-stranded 
and/or single-stranded form, although the single-stranded 
form is preferred. 
Pairs of primers designed to selectively hybridize to 
nucleic acids corresponding to a selected nucleic acid 25 
sequence are contacted with the template nucleic acid under 
conditions that permit selective hybridization. Depending 
upon the desired application, high Stringency hybridization 
conditions may be selected that will only allow hybridiza 
tion to sequences that are completely complementary to the 30 
primers. In other embodiments, hybridization may occur 
under reduced stringency to allow for amplification of 
nucleic acids contain one or more mismatches with the 
primer sequences. Once hybridized, the template-primer 
complex is contacted with one or more enzymes that facili- 35 
tate template-dependent nucleic acid synthesis. Multiple 
rounds of amplification, also referred to as “cycles,” are 
conducted until a sufficient amount of amplification product 
is produced. 
The amplification product may be detected or quantified. 40 
In certain applications, the detection may be performed by 
visual means. Alternatively, the detection may involve indi 
rect identification of the product via chemiluminescence, 
radioactive Scintigraphy of incorporated radiolabel or fluo 
rescent label or even via a system using electrical and/or 45 
thermal impulse signals (Affymax technology: Bellus, 
1994). 
A number of template dependent processes are available 
to amplify the oligonucleotide sequences present in a given 
template sample. One of the best known amplification 50 
methods is the polymerase chain reaction (referred to as 
PCRTM) which is described in detail in U.S. Pat. Nos. 
4,683, 195, 4,683.202 and 4,800,159, and in Innis et al., 
1988, each of which is incorporated herein by reference in 
their entirety. 55 
A reverse transcriptase PCRTM amplification procedure 
may be performed to quantify the amount of mRNA ampli 
fied. Methods of reverse transcribing RNA into cDNA are 
well known (see Sambrook et al., 1989). Alternative meth 
ods for reverse transcription utilize thermostable DNA poly- 60 
merases. These methods are described in WO 90/07641. 
Polymerase chain reaction methodologies are well known in 
the art. Representative methods of RT-PCR are described in 
U.S. Pat. No. 5,882,864. 
Another method for amplification is ligase chain reaction 65 
(“LCR), disclosed in European Application 320308, incor 
porated herein by reference in its entirety. U.S. Pat. No. 
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4,883,750 describes a method similar to LCR for binding 
probe pairs to a target sequence. A method based on PCRTM 
and oligonucleotide ligase assay (OLA), disclosed in U.S. 
Pat. No. 5,912,148, may also be used. 
Alternative methods for amplification of target nucleic 
acid sequences that may be used in the practice of the 
present invention are disclosed in U.S. Pat. Nos. 5,843,650, 
5,846,709, 5,846,783, 5,849,546, 5,849,497, 5,849,547, 
5,858,652, 5,866,366, 5,916,776, 5,922,574, 5,928,905, 
5,928,906, 5,932,451, 5,935,825, 5,939,291 and 5,942,391, 
GBApplication No. 2 202 328, and in PCT Application No. 
PCT/US89/01025, each of which is incorporated herein by 
reference in its entirety. 
Qbeta Replicase, described in PCT Application No. PCT/ 
US87/00880, may also be used as an amplification method 
in the present invention. In this method, a replicative 
sequence of RNA that has a region complementary to that of 
a target is added to a sample in the presence of an RNA 
polymerase. The polymerase will copy the replicative 
sequence which may then be detected. 
An isothermal amplification method, in which restriction 
endonucleases and ligases are used to achieve the amplifi 
cation of target molecules that contain nucleotide 5'-alpha 
thio-triphosphates in one strand of a restriction site may 
also be useful in the amplification of nucleic acids in the 
present invention (Walker et al., 1992). Strand Displacement 
Amplification (SDA), disclosed in U.S. Pat. No. 5,916,779, 
is another method of carrying out isothermal amplification 
of nucleic acids which involves multiple rounds of strand 
displacement and synthesis, i.e., nick translation. 
Other nucleic acid amplification procedures include tran 
Scription-based amplification systems (TAS), including 
nucleic acid sequence based amplification (NASBA) and 
3SR (Kwoh et al., 1989; Gingeras et al., PCT Application 
WO 88/10315, incorporated herein by reference in their 
entirety). European Application No. 329 822 disclose a 
nucleic acid amplification process involving cyclically syn 
thesizing single-stranded RNA (“ssRNA), ssDNA, and 
double-stranded DNA (dsDNA), which may be used in 
accordance with the present invention. 
PCT Application WO 89/06700 (incorporated herein by 
reference in its entirety) discloses a nucleic acid sequence 
amplification scheme based on the hybridization of a pro 
moter region/primer sequence to a target single-stranded 
DNA (“ssDNA) followed by transcription of many RNA 
copies of the sequence. This scheme is not cyclic, i.e., new 
templates are not produced from the resultant RNA tran 
scripts. Other amplification methods include “race' and 
“one-sided PCR' (Frohman, 1990; Ohara et al., 1989). 
2. Other Assays 
Other methods for genetic screening may be used within 
the scope of the present invention, for example, to detect 
mutations in genomic DNA, cDNA and/or RNA samples. 
Methods used to detect point mutations include denaturing 
gradient gel electrophoresis (“DGGE), restriction fragment 
length polymorphism analysis (“RFLP), chemical or enzy 
matic cleavage methods, direct sequencing of target regions 
amplified by PCRTM (see above), single-strand conformation 
polymorphism analysis (“SSCP) and other methods well 
known in the art. 
One method of Screening for point mutations is based on 
RNase cleavage of base pair mismatches in RNA/DNA or 
RNA/RNA heteroduplexes. As used herein, the term “mis 
match’ is defined as a region of one or more unpaired or 
mispaired nucleotides in a double-stranded RNA/RNA, 
RNA/DNA or DNA/DNA molecule. This definition thus 
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includes mismatches due to insertion/deletion mutations, as 
well as single or multiple base point mutations. 
U.S. Pat. No. 4,946,773 describes an RNase A mismatch 
cleavage assay that involves annealing single-stranded DNA 
or RNA test samples to an RNA probe, and subsequent 
treatment of the nucleic acid duplexes with RNase A. For the 
detection of mismatches, the single-stranded products of the 
RNase A treatment, electrophoretically separated according 
to size, are compared to similarly treated control duplexes. 
Samples containing Smaller fragments (cleavage products) 
not seen in the control duplex are scored as positive. 
Other investigators have described the use of RNase I in 
mismatch assays. The use of RNase I for mismatch detection 
is described in literature from Promega Biotech. Promega 
markets a kit containing RNase I that is reported to cleave 
three out of four known mismatches. Others have described 
using the MutS protein or other DNA-repair enzymes for 
detection of single-base mismatches. 
Alternative methods for detection of deletion, insertion or 
substitution mutations that may be used in the practice of the 
present invention are disclosed in U.S. Pat. Nos. 5,849.483. 
5,851,770, 5,866,337, 5,925,525 and 5,928,870, each of 
which is incorporated herein by reference in its entirety. 
3. Kits 
All the essential materials and/or reagents required for 
detecting a target ligand may be provided by the invention 
and may be assembled together in a kit. This generally will 
comprise an antibody or binding protein prepared in accor 
dance with the invention and designed to have affinity 
specifically to a target ligand. Also included may be buffers 
to provide the necessary mixture for binding to the ligand, 
as well as labeling means for detecting the binding. Such kits 
may also include enzymes and other reagents Suitable for 
detection of specific ligands. Such kits generally will com 
prise, in Suitable means, distinct containers for each indi 
vidual reagent or enzyme as well as for antibody or binding 
protein. 
IX. EXAMPLES 
The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventor to function well in the practice of 
the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 
the art should, in light of the present disclosure, appreciate 
that many changes can be made in the specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the spirit and scope of the invention. 
Example 1 
Fluorescence Detection and Enrichment of Cells 
Expressing schv Antibodies in the Periplasm 
The 26-10 schv antibody binds with high affinity to 
cardiac glycosides Such as digoxin and digoxigenin (K, of 
the purified, antibodies for digoxin and digoxigenin are 
0.9-0.2x10 M' and 2.4+0.4x10 M', respectively, Chen 
et al., 1999). The 26-10 scfv and its variants have been used 
extensively as a model system to understand the effect of 
mutations in the CDRs and in the framework regions on 
hapten binding (Schilbach et al., 1992; Short et al., 1995; 
Daugherty et al., 1998, 2000; Chen et al., 1999). A derivative 














promoter and with the pelB leader peptide that allows 
secretion in the E. coli periplasm. The resulting plasmid 
vector (pBAD30pelB-Dig) was transformed in the ara E. 
coli strain LMG 194 and protein synthesis was induced with 
0.2% w/v arabinose. It was observed that upon incubation 
with 200 nM of digoxigenin-BODIPYTM, cells that had been 
grown at 25° C. became strongly fluorescent and the fluo 
rescence signal was retained even after extensive washing to 
remove non-specifically bound ligand. The labeling of the 
cells with a probe having a M.W. which is significantly 
higher than the generally accepted size limit of about 600 Da 
for the permeation of hydrophilic solutes in the periplasm 
(Decad and Nikaido, 1976) raised the possibility that the 
fluorescence signal was mainly due to non-viable, perme 
abilized cells. However, staining with the viability stain 
propidium iodide, which binds specifically to membrane 
damaged cells by virtue of intercalating with the normally 
inaccessible nucleic acids, revealed that >90% of the cells 
were not permeable to the dye. This is similar to the 
proportion of intact cells in control E. coli cultures harvested 
in late exponential phase. 
Cells expressing the 26-10 antibody in the periplasm 
could be enriched from a large excess of E. coli transformed 
with vector alone in a single round of sorting. Specifically, 
LMG 194 (pBAD30pelB-Dig) were mixed with a 10,000 
fold excess of E. coli containing empty vector (pBAD30). 
The former cells are resistant to both amplicillin and 
chloramphenicol (amp, Cm) whereas the latter are resistant 
to amplicillin only (amp). 4 hours after induction with 0.2% 
w/v arabinose, the cells were then labeled with 100 nM 
digoxigenin-BODIPYTM for 1 hour and fluorescent cells 
were isolated by FACS. Following re-growth of the sorted 
cells and re-labeling as above, the population exhibited a 
five to eight-fold increase in the mean fluorescence intensity 
(FL1–20 vs FL1 =4 for the pre-sort cell mixture) The frac 
tion of ScFV-expressing clones in the enriched population 
was estimated from the number of amp clones that were 
also Cm. 80% of the amp' colonies were also Cm indicat 
ing that fluorescence labeling and cell sorting gave an 
enrichment of well over 1,000-fold in a single round 
Example 2 
Antibody Affinity Maturation 
Short et al., (1995) isolated a 26-10 mutant, designated 
A4-19, having an equilibrium dissociation constant (K) for 
digoxin of 300 pM as measured by surface plasmon reso 
nance. A4-19 contains 3 amino acid substitutions in heavy 
chain CDR1 (V:T30->P. V.D31->S and V:M34->Y). It 
was examined whether mutants with increased binding 
affinity can be obtained by periplasmic expression/FACS 
screening even when starting with an antibody that already 
exhibits very tight binding. Three light chain CDR3 residues 
that make contact (V:T91, V:P96) or are in close prox 
imity to (V:V94) the digoxin hapten (Jeffrey et al., 1993) 
were randomized using an NNS (S-G or C) strategy 
(Daugherty et al. 1998). A library of 2.5x10° transformants 
expressed in the periplasm via the pelB leader was generated 
and screened using two rounds of FACS (FIG. 2). In the first 
round of screening, cells labeled with 100 nM of the 
fluorescent probe were washed once with PBS and sorted 
using recovery mode in which the instrument collects all 
fluorescent events even if a non-fluorescent particle is 
detected in the same element of fluid as a fluorescent 
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particle. Operation in recovery mode provided a better 
assurance that very rare cells would be collected but at the 
expense of purity. 
Collected cells were re-grown, labeled, washed and then 
incubated with a 50-fold excess (50 uM) of free digoxin for 
various times (15 min to 90 min). Cells that retained the 
desired level of fluorescence were isolated by sorting using 
exclusion mode, in which, coincident fluorescent and non 
fluorescent events were rejected and thus a higher degree of 
purity was obtained. The rate of fluorescence decay for the 
pool of cells obtained following incubation with non-fluo 
rescent competitor for various times was measured. A 
slightly faster rate compared to the starting A4-19 antibody 
was observed for the earlier time points (<60 minutes 
incubation with competitor) but the rate was reduced for the 
60 min and 90 min populations. 5 random clones from the 
cell population obtained after 60 min of competition and 13 
clones from the 90 min pool were picked at random and 
sequenced (Table 1). A strong sequence consensus was 
clearly evident. The hapten binding kinetics of the purified 
antibodies were determined by SPR and the results are 
shown in Table 1. The corresponding amino acid sequences 
are given by SEQID NOs: 1-12. It should be noted that upon 
purification and analysis by gel filtration FPLC none of the 
mutants was found to dimerize. All of the mutants examined 
displayed association rate constants (k) indistinguishable 
from that of the starting A4-19 antibody (0.9+0.2x10 M'). 
The k of the clones isolated after 60 min of competition 
were the same or faster than that of A4-19. Clones isolated 
after 90 minutes of competition exhibited slower k in 
solution. One clone, 90.3, exhibited a 2-fold slower disso 
ciation rate constant resulting in a K, of 150 pM. Thus, the 
library screening methodology of the invention allowed 
specific labeling to isolate a better mutant, even when 
starting with an antibody that already exhibited a sub 
nanomolar K. Interestingly, but not surprisingly, the effect 
of the three heavy chain CDR1 mutations present in 4-19 
and the two mutations in residues 94 and 96 of the light 
chain were additive. 
TABLE 1. 
Heavy and light chain CDR3 amino acid sequences (SEQ ID NOs: 1-12) 
of mutants isolated by 60 min (clones 60.1–60.4 and 90 minutes 
(clones 90.1-90.6) off-rate selection. Number of identical clones shown in 
parenthesis. ND: Not Determined. 
Light Chain Sequence 
90 . . . 96 Off-ratefs 
Wild Type 26-10 scFv QT T H V PP 8.4 x 10' 
A14-9 QT T H V PP 2.7 x 10 
60.1 (1 clone) QT T H S PA 5.5 x 10 
60.2(2) QT T H L PT 2.8 x 10 
60.3(1) QT THT PP ND 
60.4(1) QT T H L PA ND 
90.1(1) QT T H IPT 3.2 x 10' 
90.2(1) QT T H V PP 2.7 x 10 
90.3(7) QT T H V P A 2.2 x 10 
90.4(1) QT T H I PA 1.4 x 10' 
90.5(3) QT T H L PA ND 
90.6(1) QT T H V P C ND 
Example 3 
Maximizing the Fluorescence Signal 
The fluorescence intensity of cells expressing Schv anti 
bodies in Soluble form in the periplasm was strongly depen 













With the 26-10 antibody, the maximum fluorescence inten 
sity was obtained when the cells were grown at 25° C. 
Growth at Sub-physiological temperature has several ben 
eficial effects. Expression of schv at low temperature (i.e., 
25° C.) facilitates the proper folding of the schv both 
directly, by slowing the folding pathway and indirectly by 
decreasing plasmid copy number to reduce expression load. 
Indeed, direct expression of schv at 37° C. generally yields 
little or no soluble protein (for example see Gough et al., 
1999). Outer membrane composition is also altered at non 
physiological temperatures resulting in increased permeabil 
ity (Martinez et al., 1999). Rather dramatic differences 
among various E. coli Strains were noticed. Among several 
strains tested, the highest fluorescence intensities were 
obtained in ABLETMC (FIG. 3). A preliminary analysis of 
protein expression and outer membrane protein profile in 
this strain indicated that the higher fluorescent signal was 
not due to the pcnB mutation which reduces the copy 
number of ColE1 origin plasmids but rather, due to differ 
ences in cell envelope protein composition. In fact, the 
stronger staining of ABLETMC was not related to a higher 
level of protein expression relative to other strains as 
deduced by ELISA and Western blotting. 
Fluorescent labeling under hyperosmotic conditions, 
resulted in significantly greater fluorescence (FIG. 4). A 5–7 
fold increase in fluorescence was obtained when the cells 
were incubated in 5xPBS during labeling (a mean FL1 >150 
compared to 20–30 for cells incubated in regular PBS). 
However, the increased signal came at a cost, as cell viability 
decreased considerably. Such a decrease in viability may be 
undesirable when screening highly diverse libraries of pro 
teins, whose expression may already have a deleterious 
effect on the host cell. Similarly, co-infection with filamen 
tous phages such as M13KO7 induces the phage shock 
response, which among other things, results in an increase in 
outer membrane permeability. M13 KO7 infection resulted 
in a 3-fold increase in the mean fluorescence of the popu 
lation (FIG. 5). However, as with hyperosmotic shock the 
viability of the culture, as determined by propidium iodide 
staining was somewhat decreased. 
Labeling of the cells with fluorescent ligand followed by 
incubation with a large excess of free ligand results in a 
time-dependent decrease in the mean fluorescence intensity. 
The rate of the fluorescence decay reflects the dissociation 
rate of the antibody-antigen complex (Daugherty et al., 
2000). For digoxin the rate of fluorescence decay was found 
to be about 3–4 times slower compared to the dissociation 
rate measured with the purified antibody using BIACORE. 
The lower rate of fluorescence decay compared to the 
dissociation rate of the antibody/antigen complex in vitro 
stems from several effects including the collision frequency 
between ligands and cells, the concentration of antibody in 
the periplasm and, of course, the rate of diffusion through the 
outer membrane (see Martinez et al., (1996) for an analysis 
of kinetics in the periplasmic space). As may be expected, 
the ratio of the rate of fluorescence decay in the periplasm 
relative to the in vitro determined k, rate is antigen depen 
dent. 
Example 4 
Analysis and Screening of Repertoire Antibody 
Libraries by FACS 
Antibodies can be isolated de novo, i.e., without animal 
immunization, by Screening large, repertoire libraries that 
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contain a wide variety of antibody sequences. The screening 
of such large libraries is well established (Nissimetal. 1994, 
Winter et al. 1994, Griffith et al. 1994, Knappik et al. 2000). 
It was important to establish: (a) How anchor-less display 
(ALD) compares with the phage display technology in terms 
of allowing the isolation of high affinity clones and (b) 
whether ALD can be used to screen highly diverse libraries. 
So far all the large antibody repertoire libraries available 
have been constructed for use with phage display. The 
inventors discovered that they could take advantage of the 
fact that libraries constructed for phage display also allow 
the expression of proteins within the bacterial periplasmic 
space. In particular, for low protein copy number display on 
filamentous bacteriophage, recombinant polypeptides are 
expressed as N-terminal fusions to pIII. During the course of 
phage biogenesis, pIII fusions are first targeted to the 
periplasm and anchored in the inner membrane by a small 
C-terminal portion of p. As phage are released, the 
schv-pIII fusion is incorporated alongside wild-type plII at 
the terminus of the phage, thereby concluding the assembly 
process (Rakonjac and Model, 1998; Rakonjac et al., 1999) 
In the most widely used vectors for phage display an amber 
codon is placed between the N-terminal scFv and the plII 
gene. Thus, in a suitable E. Coli Suppressor Strain, full 
length scFV-pII fusion protein is produced for displaying 
the schv whereas in a non-supressor strain only soluble schv 
is expressed. The degree of Suppression varies with vector 
and strain but tends to allow only 10% read-through. Thus, 
as a consequence of the biology of phage display, all 
amber-codon containing libraries result in a degree of peri 
plasmic expression regardless of host. Hence, it was of great 
interest to explore whether FACS can aid the isolation of 
ligand binding proteins from pre-existing, highly diverse, 
naive libraries (Griffiths et al., 1994; Vaughan et al., 1996; 
Sheets et al., 1998; Pini et al., 1998; de Haard et al., 1999; 
Knappik et al., 2000; Sblattero and Bradbury, 2000). 
Conventional Screening of the phage library by phage 
panning enriched phage expressing scFVS specific for the 
cardiac glycoside digoxin (FIG. 6A, B) from a naive anti 
body repertoire library. The panning process was performed 
on a BSA conjugate and the screening was performed on an 
ovalbumin conjugate to reduce the incidence of protein and 
hapten-protein interface binders. 24 positive isolates from 
pan 4 shared the same fingerprint and DNA sequencing of 6 
clones confirmed the same heavy and light chain sequence 
(“dig1') with one of six (“dig2) having a unique HCDR3 
and LCDR3 combination (FIG. 7). Repeated screening of 
the phage library both under identical and under different 
conditions resulted only in the isolation of clones with the 
same DNA fingerprint. 
FACS analysis of the phage rescued in E. coli ABLETMC 
after each round of panning reveals an increase in mean 
fluorescence at round 3 which mirrors the phage ELISA 
signals (FIG. 6C). Significant enrichment of binding clones 
using a single round of FACS was obtained starting with the 
population obtained from the 3" round of phage panning. 
This result is consistent with the enrichment profiles 
obtained during the course of the panning experiment. FACS 
screening and sorting 10° cells from rounds 3, 4 and 5 
resulted in the isolation of positive clones at a frequency of 
30, 80 and 100% respectively 
Out of 14 clones isolated by FACS from the round 3 
population 5 were found to be positive for binding to 
digoxin. Importantly three of the clones corresponded to a 
different antibody that was missed by phage panning (herein 













This result demonstrates that FACS screening of libraries 
expressed in the periplasmic space and labeled with fluo 
rescent ligands results in the isolation of clones that cannot 
be isolated by other library screening methodologies. 
Example 5 
Materials And Methods 
A. Strains and Plasmids 
E. coli strains TG1 and HB2151 were provided with the 
Griffin library. ABLETMC and ABLETMK were purchased 
from Stratagene and helper phage M13K07 from Pharmacia. 
A positive control for FACS analysis of a phage display 
vehicle was constructed by replacing a pre-existing Schv in 
pHEN2 with the 26.10 scEv to create pHEN2.dig. The 
negative control was pHEN2.thy bearing the anti-thyroglo 
bulin scFv provided with the Griffin.1 library. The P 
vector was a derivative of plMS120 (Hayhurst, 2000). 
B. Phage Panning 
The Griffin.1 library is a semi-synthetic scFv library 
derived from a large repertoire of human heavy and light 
chains with part or all of the CDR3 loops randomly mutated 
and recombined in vivo (Griffiths et al., 1994). The library 
was rescued and Subjected to five rounds of panning accord 
ing to the web-site instruction manual (www.mrc-cpe.ca 
m.ac.uk/-phage/glp.html), Summarized in Example 6. 
below. Immunotubes were coated with 10 ugml digoxin 
BSA conjugate and the neutralized eluates were halved and 
used to infect either TG-1 for the next round of phage 
panning, or ABLETM C for FACS analysis. 
Eluate titers were monitored to indicate enrichment of 
antigen binding phage. To confirm reactivity, a polyclonal 
phage ELISA of purified, titer normalized phage stocks 
arising from each round was performed on digoxin-ovalbu 
min conjugate. The percentage of positive clones arising in 
rounds 3, 4 and 5 was established by monoclonal phage 
ELISA of 96 isolates after each round. A positive was 
arbitrarily defined as an absorbance greater than 0.5 with a 
background signal rarely above 0.01. Mval fingerprinting 
was applied to 24 positive clones from rounds 3, 4 and 5. 
C. FACS Screening 
An aliquot of phagemid containing, ABLETMC glycerol 
stock was scraped into 1 ml of 2xTY (2% glucose, 100 
ugml ampicillin) to give an OD at 600 nm of approximately 
0.1 cm. After shaking vigorously at 37° C. for 2 h, IPTG 
was added to 1 mM and the culture shaken at 25° C. for 4 
h. 50 ul of culture was labeled with 100 nM BODIPYTM 
digoxigenin (Daugherty et al., 1999) in 1 ml of 5xPBS for 
1 hat room temperature with moderate agitation. For the last 
10 min of labeling, propidium iodide was added to 2 ugml. 
Cells were pelleted and resuspended in 100 ul of labeling 
mix. Scanning was performed with Becton-Dickinson FAC 
Sort, collecting 10 events at 1500 s. 
For FACS library sorting, the cells were grown in terrific 
broth and induced with 0.1 mMIPTG. Sorting was per 
formed on 10° events (107 for round 2) in exclusion mode at 
1000 s. Collected sort liquor was passed through 0.7 um 
membrane filters and colonies allowed to grow after placing 
the filter on top of SOC agar plus appropriate antibiotics at 
30° C. for 24 h. 
D. Analysis of Phage Clones 
Screening phage particles by ELISA is Summarized as 
follows. Binding of phage in ELISA is detected by primary 
sheep anti-M13 antisera (CP laboratories or 5 prime 3 
prime) followed by a horseradish peroxidase (HRP) conju 
gated anti-sheep antibody (Sigma). Alternatively, a HRP 
ice 
US 7,083,945 B1 
33 
anti-M13 conjugate can be used (Pharmacia). Plates can be 
blocked with 2% MPBS or 3% BSA-PBS. For the poly 
clonal phage ELISA, the technique is generally as follows: 
coat MicroTest III flexible assay plates (Falcon) with 100 ul 
per well of protein antigen. Antigen is normally coated 
overnight at 4° C. at a concentration of 10–100 g/ml in 
either PBS or 50 mM sodium hydrogen carbonate, pH 9.6. 
Rinse wells 3 times with PBS, by flipping over the ELISA 
plates to discard excess liquid, and fill well with 2% MPBS 
or 3% BSA-PBS for 2 hr at 37° C. Rinse wells 3 times with 
PBS. Add 10 ul PEG precipitated phage from the stored 
aliquot of phage from the end of each round of selection 
(about 10' t?u.). Make up to 100 ul with 2% MPBS or 3% 
BSA-PBS. Incubate for 90 minatrt. Discard the test solution 
and wash three times with PBS-0.05% Tween 20, then 3 
times with PBS. Add appropriate dilution of HRP-anti-M13 
or sheep anti-M13 antisera in 2% MPBS or 3% BSA-PBS. 
Incubate for 90 min at rt, and wash three times with 
PBS-0.05% Tween 20, then 3 times with PBS. If sheep 
anti-M13 antisera is used, incubate for 90 min at rt, with a 
suitable dilution of HRP-anti-sheep antisera in 2% MPBS or 
3% BSA and wash three times with PBS-0.05% Tween 20, 
then 3 times with PBS. Develop with substrate solution (100 
ug/ml TMB in 100 mM sodium acetate, pH 6.0, add 10 ul of 
30% hydrogen peroxide per 50 ml of this solution directly 
before use). Add 100 ul to each well and leave at rt for 10 
min. A blue color should develop. Stop the reaction by 
adding 50 ul 1 M sulfuric acid. The color should turn yellow. 
Read the OD at 450 nm and at 405 nm. Subtract OD 405 
from OD 450. 
Monoclonal phage ELISA can be summarized as follows. 
To identify monoclonal phage antibodies the pHEN phage 
particles need to be rescued: Inoculate individual colonies 
from the plates in C 10 (after each round of selection) into 
100 ul 2xTY containing 100 ug/ml amplicillin and 1% 
glucose in 96-well plates (Corning Cell Wells) and grow 
with shaking (300 rpm.) overnight at 30°C. Use a 96-well 
transfer device to transfer a small inoculum (about 2 ul) from 
this plate to a second 96-well plate containing 200 ul of 
2xTY containing 100 ug/ml amplicillin and 1% glucose per 
well. Grow shaking at 37°C. for 1 hr. Make glycerol stocks 
of the original 96-well plate, by adding glycerol to a final 
concentration of 15%, and then storing the plates at -70° C. 
To each well (of the second plate) add VCS-M13 or 
M13KO7 helper phage to an moi of 10. Stand for 30 min at 
37° C. Centrifuge at 1,800 g. for 10 min, then aspirate off the 
supernatant. Resuspend pellet in 200 ul 2xTY containing 
100 g/ml amplicillin and 50 g/ml kanamycin. Grow shak 
ing overnight at 30° C. Spin at 1,800 g for 10 min and use 
100 ul of the supernatant in phage ELISA as detailed above. 
Production of soluble antibody fragments is summarized 
as follows: the selected pHEN needs to be infected into 
HB2151 and then induced to give soluble expression of 
antibody fragments for ELISA. From each selection take 10 
ul of eluted phage (about 10 t.u.) and infect 200 ul expo 
nentially growing HB2151 bacteria for 30 min at 37° C. 
(waterbath). Plate 1, 10, 100 ul, and 1:10 dilution on TYE 
containing 100 g/ml amplicillin and 1% glucose. Incubate 
these plates overnight at 37°C. Pick individual colonies into 
100 ul 2xTY containing 100 ug/ml amplicillin and 1% 
glucose in 96-well plates (Corning Cell Wells), and grow 
with shaking (300 rpm.) overnight at 37°C. A glycerol stock 
can be made of this plate, once it has been used to inoculate 
another plate, by adding glycerol to a final concentration of 
15% and storing at -70°C. Use a 96-well transfer device to 
transfer a small inocula (about 2 ul) from this plate to a 













ing 100 g/ml amplicillin and 0.1% glucose per well. Grow 
at 37° C., shaking until the OD at 600 nm is approximately 
0.9 (about 3 hr). Once the required OD is reached add 25 ul 
2xTY containing 100 ug/ml amplicillin and 9 mM IPTG 
(final concentration 1 mM IPTG). Continue shaking at 30° 
C. for a further 16 to 24hr. Coat MicroTest III flexible assay 
plates (Falcon) with 100 ul per well of protein antigen. 
Antigen is normally coated overnight at rt at a concentration 
of 10–100 ug/ml in either PBS or 50 mM sodium hydrogen 
carbonate, pH 9.6. The next day rinse wells 3 times with 
PBS, by flipping over the ELISA plates to discard excess 
liquid, and block with 200 ul per well of 3% BSA-PBS for 
2 hr at 37° C. Spin the bacterial plate at 1,800 g for 10 min 
and add 100 ul of the supernatant (containing the soluble 
sch v) to the ELISA plate for 1 hr at rt. Discard the test 
solution and wash three times with PBS. Add 50 ul purified 
9E10 antibody (which detects myc-tagged antibody frag 
ments) at a concentration of 4 ug/ml in 1% BSA-PBS and 50 
ul of a 1:500 dilution of HRP-anti-mouse antibody in 1% 
BSA-PBS. Incubate for 60 min at rt, and wash three times 
with PBS-0.05% Tween 20, then 3 times with PBS. Develop 
with substrate solution (100 ug/ml TMB in 100 mM sodium 
acetate, pH 6.0. Add 10 ul of 30% hydrogen peroxide per 50 
ml of this solution directly before use). Add 100 ul to each 
well and leave at rt for 10 min. A blue color should develop. 
Stop the reaction by adding 50 ul 1 M sulphuric acid. The 
color should turn yellow. Read the OD at 450 nm and at 405 
nm. Subtract OD 405 from OD 450. 
Inserts in the library can be screened by PCR screening 
using the primers designated LMB3: CAG GAA ACA GCT 
ATGAC (SEQ ID NO:13) and Fd seq1: GAA TTT TCT 
GTATGAGG (SEQID NO:14). For sequencing of the VH 
and VL, use is recommend of the primers FOR LinkSeq: 
GCC ACC TCC GCC TGA ACC (SEQ ID NO:15) and 
pHEN-SEQ: CTA TGC GGC CCC ATT CA (SEQ ID 
NO:16). 
Example 6 
Summary of Methodology for Use of the Griffin. 1 
Library 
Methodology for using the Griffin.1 library can be sum 
marized as follows. The Griffin.1 library is a schv phagemid 
library made from synthetic V-gene segments. The library 
was made by recloning the heavy and light chain variable 
regions from the lox library vectors (Griffiths et al., EMBO 
J, 1994) into the phagemid vector pHEN2. A kit for use of 
the library will contain a tube of the synthetic schv Library 
(1 ml), a glycerol stock of the positive control (TG1 con 
taining an anti-thyroglobulin clone), a glycerol stock of the 
negative control (TG1 containing pHEN2), a glycerol stock 
of E. coli TG1 (Gibson, 1984) suppressor strain (K12, 
del(lac-pro), supE, thi, hsdD5/F"tral D36, proA+B+, lacIq, 
laczdelM15) for propagation of phage particles (the strain 
Supplied is a T-phage resistant variant of this), a glycerol 
stock of E. coli HB2151 (Carter et al., 1985) and non 
Suppressor strain (K12, ara, del(lac-pro), thi/F"proA+B+, 
lacIq, laczdelM15) for expression of antibody fragments. 
The library is kept frozen at -70° C. until needed. 
The strains are plated and then are grown up as overnight 
cultures (shaking at 37°C.) of each in 2xTY containing 100 
ug/ml ampicillin and 1% glucose. Cultures are diluted 1:100 
with 2xTY (2xTY is 16 g Typtone, 10 g Yeast Extract and 
5 g NaCl in 1 liter) containing 100 g/ml amplicillin and 1% 
glucose and the phagemids rescued by following the proce 
dures described below. A 1:100 mixture is used of positive 
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and the negative control together for one round of selection 
on immunotubes, coated with thyroglobulin. 
The protocol for use of the library is summarized as 
follows. Phage/phagemid infect F+-E. coli via the sex pili. 
For sex pili production and efficient infection E. coli must be 
grown at 37° C. and be in log phase (OD at 600 nm of 
0.4–0.6). Throughout the following protocol such a culture 
is needed. It can be prepared as follows: transfer a bacterial 
colony from a minimal media plate into 5 ml of 2xTY 
medium and grow shaking overnight at 37° C. Next day, 
subculture by diluting 1:100 into fresh 2xTY medium, grow 
shaking at 37° C. until OD 0.4–0.6 and then infect with 
phage. A variety of helper phages are available for the rescue 
of phagemid libraries. VCS-M13 (Stratagene) and M13KO7 
(Pharmacia) can be purchased in Small aliquots, larger 
quantities for rescue of phagemid libraries can be prepared 
as follows: Infect 200 ul E. coli TG1 (or other suitable strain) 
at OD 0.2 with 10 ul serial dilutions of helper phage (in order 
to get well separated plaques) at 37° C. (waterbath) without 
shaking for 30 min. Add to 3 ml molten H-top agar (42°C.) 
and pour onto warm TYE (note 7) plates. Allow to set and 
then incubate overnight at 37° C. Pick a small plaque into 
3–4 ml of an exponentially growing culture of TG1 (see 
above). Grow for about 2 hr shaking at 37°C. Inoculate into 
500 ml 2xTY in a 2 liter flask and grow as before for 1 hr 
and then add kanamycin (25 ug/ml in water) to a final 
concentration of 50–70 ug/ml. Grow for a further 8–16 hr. 
Spin down bacteria at 10,800 g for 15 min. To the phage 
supernatant add /s Volume PEG/NaCl (20% polyethylene 
glycol 6000-2.5 M NaCl) and incubate for a minimum of 30 
min on ice. Spin 10,800 g for 15 min. Resuspend pellet in 
2 ml TE and filter sterilise the stock through a 0.45 unfilter 
(Minisart NML; Sartorius). Titre the stock and then dilute to 
about 1x1012 p.fu./ml. Store aliquots at -20°C. All spins 
are performed at 4°C., unless otherwise stated. 
For growth of the library, the procedure is summarized as 
follows: inoculate the whole of the bacterial library stock 
(about 1x10' clones) into 500 ml 2xTY containing 100 
ug/ml amplicillin and 1% glucose. Grow with shaking at 37° 
C. until the OD at 600 nm is 0.5, this should take about 1.5–2 
hours. Infect 25 ml (1x1010 bacteria) from this culture with 
VCS-M13 or M13KO7 helper phage by adding helper phage 
in the ratio of 1:20 (number of bacterial cells: helper phage 
particles, taking into account that 1 OD bacteria at 600 
nm around 8x108 bacteria/ml). 
Spin the infected cells at 3,300 g for 10 min. Resuspend 
the pellet gently in 30 ml of 2xTY containing 100 ug/ml 
ampicillin and 25 g/ml kanamycin. Add 470 ml of pre 
warmed 2xTY containing 100 lug/ml amplicillin and 25 
ug/ml kanamycin and incubate shaking at 30° C. overnight. 
The phage can be concentrated and any soluble antibodies 
removed (as in TG1 Suppression of the amber stop codon 
encoded at the junction of the antibody gene and g|II is 
never complete) by precipitating with Polyethylene glycol 
(PEG) 6000. Spin the culture from A6 at 10,800 g for 10 min 
(or 3.300 g for 30 min). Add /S volume PEG/NaCl (20% 
Polyethylene glycol 6000, 2.5 M NaCl) to the supernatant. 
Mix well and leave for 1 hr or more at 4° C. Spin 10,800 g 
for 30 min. Resuspend the pellet in 40 ml water and add 8 
ml PEG/NaCl. Mix and leave for 20 min or more at 4° C. 
Spin at 10,800 g for 10 minor 3.300 g for 30 min and then 
aspirate off the Supernatant. Respin briefly and then aspirate 
off any remaining PEG/NaCl. Resuspend the pellet in 5 ml 
PBS and spin 11,600 g for 10 min in a microcentrifuge to 
remove most of the remaining bacterial debris. Store the 
phage supernatant at 4°C. for short term storage or in PBS, 














phage stock dilute 1 ul phage in 1 ml PBS and use 1 ul of 
this to infect 1 ml of TG1 at an OD600 0.4–0.6. Plate 50 ul 
of this, 50 ul of a 1:102 dilution and 50 ul of a 1:104 on TYE 
plates containing 100 ug/ml amplicillin and 1% glucose and 
grow overnight at 37° C. Phage stock should be 10° 10'/ 
ml. 
Selection on immunotubes is Summarized as follows. 
Coat Nunc-immunotube (Maxisorp Cat. No. 4-44202) over 
night with 4 ml of the required antigen. The efficiency of 
coating can depend on the antigen concentration, the buffer 
and the temperature. Usually 10–100 g/ml antigen in PBS 
or 50 mM sodium hydrogen carbonate, pH 9.6 at room 
temperature (rt), is used. Next day wash tube 3 times with 
PBS (simply pour PBS into the tube and then pour it 
immediately out again). Fill tube to brim with 2% MPBS. 
Cover and incubate at 37°C. (or rt according to the stability 
of antigen) for 2 hr to block. Wash tube 3 times with PBS. 
Add 10' to 10" cfu. phage, from A13, in 4 ml of 2% MPBS. 
Incubate for 30 min at rt rotating continuously on an 
under-and-over turntable and then stand for at least a further 
90 min at rt. Throw away the unbound phage in the super 
natant. For the first round of selection wash tubes 10 times 
with PBS containing 0.1% Tween-20, then 10 times with 
PBS to remove the detergent. Each washing step is per 
formed by pouring buffer in and immediately out. For the 
second and Subsequent rounds of selection wash tubes 20 
times with PBS containing 0.1% Tween-20, then 20 times 
with PBS. Shake out the excess PBS from the tube and elute 
phage by adding 1 ml 100 mM triethylamine (700 ul 
triethylamine (7.18 M) in 50 ml water, diluted on day of use) 
and rotating continuously for 10 min on an under-and-over 
turntable. During the incubation, tubes are prepared with 0.5 
ml 1M Tris, pH 7.4 ready to add the eluted 1 ml phage, from 
7, for quick neutralisation. Phage can be stored at 4°C. or 
used to infect TG1 as described above. After elution add 
another 200 ul of 1M Tris, pH 7.4 to the immunotube to 
neutralise the remaining phage in the tube. Take 9.25 ml of 
an exponentially growing culture of TG 1 and add 0.75 ml of 
the eluted phage. Also add 4 ml of the TG1 culture to the 
immunotube. Incubate both cultures for 30 min at 37° C. 
(waterbath) without shaking to allow for infection. Pool the 
10 ml and 4 ml of the infected TG1 bacteria and take 100 ul 
to make 4–5 100-fold serial dilutions. Plate these dilutions 
on TYE containing 100 ug/ml amplicillin and 1% glucose. 
Grow overnight at 37°C. Take the remaining infected TG1 
culture and spin at 3,300 g for 10 min. Resuspend the 
pelleted bacteria in 1 ml of 2xTY and plate on a large Nunc 
Bio-Assay dish (Gibco-BRL (note 8)) of TYE containing 
100 g/ml amplicillin and 1% glucose. Grow at 30° C. 
overnight, or until colonies are visible. 
For further rounds of selection, add 5–6 ml of 2xTY, 15% 
glycerol to the Bio-Assay dish of cells and loosen the cells 
with a glass spreader. After inoculating 50–100 ul of the 
scraped bacteria to 100 ml of 2xTY containing 100 g/ml 
ampicillin and 1% glucose, store the remaining bacteria at 
-70° C. Once again it is a good idea to check starting OD 
at 600 nm is <0.1. Grow the bacteria with shaking at 37° C. 
until the OD at 600 nm is 0.5 (about 2 hr). Infect 10 ml of 
this culture with VCS-M13 or M13KO7 helper phage by 
adding helper phage in the ratio of 1:20 (number of bacterial 
cells: helper phage particles, taking into account that 1 OD 
bacteria at 600 nm around 8x108 bacteria/ml). Incubate 
without shaking in a 37°C. water bath for 30 min. Spin the 
infected cells at 3,300 g for 10 min. Resuspend the pellet 
gently in 50 ml of 2xTY containing 100 ug/ml amplicillin 
and 25 ug/ml kanamycin and incubate shaking at 30° C. 
overnight. Take 40 ml of the overnight culture and spin at 
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10,800 g for 10 min or 3.300 g for 30 min. Add /S volume 
(8 ml) PEG/NaCl (20% Polyethylene glycol 6000, 2.5 M 
NaCl) to the supernatant. Mix well and leave for 1 hr or 
more at 4°C. Spin 10,800 g for 10 minor 3.300 g for 30 min 
and then aspirate off the supernatant. Respin briefly and then 5 
aspirate off any remaining dregs of PEG/NaCl. Resuspend 
the pellet in 2 ml PES and spin 11, 600 g for 10 min in a 
micro centrifuge to remove most of the remaining bacterial 
debris. 1 ml of this phage can be stored at 4°C. and the other 
1 ml aliquot can be used for the next round of selection. 
Repeat the selection for another 2–3 rounds. 
10 
Screening phage particles by ELISA is Summarized as 
follows. Binding of phage in ELISA is detected by primary 
sheep anti-M13 antisera (CP laboratories or 5 prime-3 15 
prime) followed by a horseradish peroxidase (HRP) conju 
gated anti-sheep antibody (Sigma). Alternatively, a HRP 
anti-M13 conjugate can be used (Pharmacia). Plates can be 
blocked with 2% MPBS or 3% BSA-PBS. For the poly 
clonal phage ELISA, the technique is generally as follows: 20 
coat MicroTest III flexible assay plates (Falcon) with 100 ul 
per well of protein antigen. Antigen is normally coated 
overnight at rt at a concentration of 10–100 ug/ml in either 
PBS or 50 mM sodium hydrogen carbonate, pH 9.6. Rinse 
wells 3 times with PBS, by flipping over the ELISA plates 
to discard excess liquid, and block with 200 ul per well of 
2% MPBS or 3% BSA-PBS for 2 hr at 37° C. Rinse wells 
3 times with PBS. Add 10 ul PEG precipitated phage from 
the stored aliquot of phage from the end of each round of 
selection (about 10' cfu.). Make up to 100 ul with 2% 
MPBS or 3% BSA-PBS. Incubate for 90 min at rt. Discard 
the test Solution and wash three times with PBS-0.05% 
Tween 20, then 3 times with PBS. Add appropriate dilution 
of HRP-anti-M13 or sheep anti-M13 antisera in 2% MPBS is 
or 3% BSA-PBS. Incubate for 90 min at rt, and wash three 
times with PBS-0.05% Tween 20, then 3 times with PBS. If 
sheep anti-M13 antisera is used, incubate for 90 min at rt, 
with a suitable dilution of HRP-anti-sheep antisera in 2% 
MPBS or 3% BSA and wash three times with PBS-0.05% 40 
Tween 20, then 3 times with PBS. Develop with substrate 
solution (100 ug/ml TMB in 100 mM sodium acetate, pH 
6.0. Add 10 ul of 30% hydrogen peroxide per 50 ml of this 
solution directly before use). Add 100 ul to each well and 
leave at rt for 10 min. A blue colour should develop. Stop the 4s 
reaction by adding 50 ul 1 M sulphuric acid. The colour 
should turn yellow. Read the OD at 450 nm and at 405 nm. 
Subtract OD 405 from OD 450. 
Monoclonal phage ELISA can be summarized as follows. 
To identify monoclonal phage antibodies the pHEN phage 50 
particles need to be rescued: Inoculate individual colonies 
from the plates in C10 (after each round of selection) into 
100 ul 2xTY containing 100 ug/ml amplicillin and 1% 
glucose in 96-well plates (Corning Cell Wells) and grow 
with shaking (300 rpm.) overnight at 37°C. Use a 96-well 55 
transfer device to transfer a small inoculum (about 2 ul) from 
this plate to a second 96-well plate containing 200 ul of 
2xTY containing 100 ug/ml amplicillin and 1% glucose per 
well. Grow shaking at 37°C. for 1 hr. Make glycerol stocks 
of the original 96-well plate, by adding glycerol to a final 60 
concentration of 15%, and then storing the plates at -70° C. 
To each well (of the second plate) add 25 Jul 2xTY contain 
ing 100 ug/ml ampicillin, 1% glucose and 109 pfu VCS 
M13 or M13KO7 helper phage. Stand for 30 min at 37°C., 
then shake for 1 hr at 37° C. Spin 1,800 g. for 10 min, then 65 
aspirate off the supernatant. Resuspend pellet in 200 ul 
2xTY containing 100 g/ml amplicillin and 50 ug/ml kana 
25 
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mycin. Grow shaking overnight at 30° C. Spin at 1,800 g for 
10 min and use 100 ul of the supernatant in phage ELISA as 
detailed above. 
Production of soluble antibody fragments is summarized 
as follows: the selected pHEN needs to be infected into 
HB2151 and then induced to give soluble expression of 
antibody fragments for ELISA. From each selection take 10 
ul of eluted phage (about 105 t.u.) and infect 200 ul 
exponentially growing HB32151 bacteria for 30 min at 37° 
C. (waterbath). Plate 1, 10, 100 ul, and 1:10 dilution on TYE 
containing 100 ug/ml amplicillin and 1% glucose. Incubate 
these plates overnight at 37°C. Pick individual colonies into 
100 ul 2xTY containing 100 ug/ml amplicillin and 1% 
glucose in 96-well plates (Corning Cell Wells), and grow 
with shaking (300 rpm.) overnight at 37°C. A glycerol stock 
can be made of this plate, once it has been used to inoculate 
another plate, by adding glycerol to a final concentration of 
15% and storing at -70° C. Use a 96-well transfer device to 
transfer a small inocula (about 2 ul) from this plate to a 
second 96-well plate containing 200 ul fresh 2xTY contain 
ing 100 g/ml amplicillin and 0.1% glucose per well. Grow 
at 37° C., shaking until the OD at 600 nm is approximately 
0.9 (about 3 hr). Once the required OD is reached add 25 ul 
2xTY containing 100 ug/ml amplicillin and 9 mM IPTG 
(final concentration 1 mM IPTG). Continue shaking at 30° 
C. for a further 16 to 24hr. Coat MicroTest III flexible assay 
plates (Falcon) with 100 ul per well of protein antigen. 
Antigen is normally coated overnight at rt at a concentration 
of 10–100 ug/ml in either PBS or 50 mM sodium hydrogen 
carbonate, pH 9.6. The next day rinse wells 3 times with 
PBS, by flipping over the ELISA plates to discard excess 
liquid, and block with 200 ul per well of 3% BSA-PBS for 
2 hr at 37° C. Spin the bacterial plate at 1,800 g for 10 min 
and add 100 ul of the supernatant (containing the soluble 
sch v) to the ELISA plate for 1 hr at rt. Discard the test 
solution and wash three times with PBS. Add 50 ul purified 
9E10 antibody (which detects myc-tagged antibody frag 
ments) at a concentration of 4 ug/ml in 1% BSA-PBS and 50 
ul of a 1:500 dilution of HRP-anti-mouse antibody in 1% 
BSA-PBS. Incubate for 60 min at rt, and wash three times 
with PBS-0.05% Tween 20, then 3 times with PBS. Develop 
with substrate solution (100 ug/ml TMB in 100 mM sodium 
acetate, pH 6.0. Add 10 ul of 30% hydrogen peroxide per 50 
ml of this solution directly before use). Add 100 ul to each 
well and leave at rt for 10 min. A blue colour should develop. 
Stop the reaction by adding 50 ul 1 M sulphuric acid. The 
colour should turn yellow. Read the OD at 450 nm and at 
405 nm. Subtract OD 405 from OD 450. 
Inserts in the library can be screened by PCR screening 
using the primers designated LMB3: CAG GAA ACA GCT 
ATGAC (SEQ ID NO:13) and Fd seq1: GAA TTT TCT 
GTATGAGG (SEQ ID NO:14). For sequencing of the VH 
and VL, use is recommend of the primers FOR LinkSeq: 
GCC ACC TCC GCC TGA ACC (SEQ ID NO:15) and 
pHEN-SEQ: CTA TGC GGC CCC ATT CA (SEQ ID 
NO:16). 
Example 7 
Isolation of scFV Antibodies Specific to TNB from 
a Repertoire Library 
This example Summarizes the screening of a repertoire 
antibody library to the ligand TNB (trinitrobenzene). 
Library screening was initiated by first carrying out three 
rounds of phage panning of a repertoire library (Griflin-1 
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library) using standard protocols (see example 6, also 
described in www.mrc-cpe.cam.ac.uk/~phage/glp.html). 
Phage rescued from various rounds of panning were used to 
infect the E. coli ABLE C. The cells were grown to 
mid-exponential phase, induced for expression of ScFV 
antibodies as described above and labeled with 100 nM 
TNBS conjugated to the fluorescent dye Cy5. The labeled 
cells were analyzed by flow cytometry using a Cytomation 
MoFlo instrument equipped with a 5 mM diode laser emit 
ting at 633 nm. Highly fluorescent clones were isolated on 
membrane filters and analyzed further. Three out of 10 
clones isolated by FACS were analyzed further and found to 
exhibit strong binding to a TNBS-BSA conjugate. Sequence 
analysis confirmed that one of the TNBS specific clones had 
also been found by phage display. However, the two other 
clones isolated by the present invention (periplasmic expres 
sion of the library and FACS screening) did not correspond 
to any of the clones isolated by phage panning. 
Example 8 
Detection of Oligonucleotide Probes by Antibodies 
Expressed in the E. coli Periplasm 
This example shows that modified oligonucleotides can 
diffuse through the outer membrane of bacteria. An oligo 
nucleotide with the sequence 5'-digoxigenin-AAAAA-fluo 
roscein-3' (designated dig-5A-FL, molecular weight of 
2.384 Da, SEQID NO:22) containing four nuclease resistant 
phosphorothioate linkages between the five A residues was 
synthesized and purified (RP HPLC) by Integrated DNA 
Technologies, IA. The digoxigenin moiety of this oligo 
nucleotide can be recognized by scFv antibodies specific to 
digoxin (anti-digoxin Scv). Cells expressing the anti 
digoxin schv in the periplasm may bind 5A-F 1 which in turn 
should render the cells fluorescent, provided that the probe 
molecule can diffuse through the outer membrane. 
ABLETMC cells expressing periplasmic sclv specific for 
either atrazine (Hayhurst 2000) as a negative control (FIG. 
8, panels i and iii) or digoxigenin (FIG. 8, panels ii and iv) 
were incubated in 5x strength PBS (see example 3) together 
with either 100 nM of digoxigenin-BODIPYTM or 100 nM of 
dig-5A-FL. Propidium iodine was also added to serve as a 
viability stain. Viable cells were gated on the basis of 
propidium iodine exclusion (to identify cells with an intact 
membrane) and side scatter. Approximately 10,000 cells 
were analyzed at a rate of 1,000 events per second. The 
resulting data are shown in FIG. 8. Cells expressing an 
unrelated anti-atrazine antibody that does not bind to the 
probe exhibited only background fluorescence. In contrast, 
cells displaying the anti-digoxin scFv antibody became 
clearly labeled with both the digoxigenin-BODIPYTM as 
well as with 5-A-FL. The latter probe gave a signal that was 
clearly higher than that observed with the control cells. Even 
though 5-A-FL gave a lower fluorescence intensity com 
pared to the Smaller and uncharged the digoxigenin-BO 
DIPY, the signal obtained with the former probe was suffi 
cient for the screening of schv libraries by FACS. 
Example 9 
Flow Cytometric Discrimination of E. coli 
Expressing the Fusarium Solani Lipase Cutinase 
Using Commercial Fluorescent Substrates 
This example demonstrates that commercially available 













cells displaying the relevant enzymes in their periplasm. 
Surprisingly, the fluorescent product of these reactions is 
sufficiently retained within the cell to allow for the discrimi 
nation and selection of enzyme expressing E. coli from 
non-enzyme expressing bacteria. 
The gene encoding Fusarium Solani lipase cutinase was 
constructed by total gene synthesis and placed downstream 
of the strong inducible promoter pBAD in plasmid 
pBAD18Cm. Protein expression from the pBAD promoter is 
beneficial for the screening of protein libraries by FACS 
(Daugherty et al. 1999). The resulting plasmid encoding the 
cutinase gene was designated pKG3-53-1. pKG3-53-1, and 
pBAD18 Cm as a control, were both transformed into DH.5a. 
In this example, the ability to discriminate cells expressing 
cutinase (DH5a(pKG3-53-1)) from control cells was deter 
mined using two different commercially available sub 
strates: Fluorescein dibutyrate or LysoSensor Green DND 
189 (LSG) (both from Molecular Probes, OR). The latter is 
a positively charged fluorescent probe that detects pH 
changes in the cell occurring due to ester hydrolysis by the 
enzyme. 
Cells were grown overnight with vigorous shaking at 37° 
C. in terrific broth/chloramphenicol 50 lug/ml (TB/Cm). 
Subcultures were made from 100% of overnight culture in 
10 ml of TB/Cm (50 ug/ml). These subcultures were grown 
with vigorous shaking at 37° C. to ODoo-0.6. Four ml 
aliquots of the subcultures were pelleted at 3650 rpm for 20 
minutes in a Beckman Allegra 6R Centrifuge. The Superna 
tant was removed, and the pellets were resuspended in 4 ml 
of M9 minimal media containing 0.2% glucose and 
chloramphenicol (Cm) at 50 g/ml. Arabinose, from a 20% 
stock, was added to a final concentration of 0.2%. The 
cultures were induced at 25°C. with vigorous shaking for 4 
hours. Subsequently, 2 ml aliquots of the induced cultures 
were pelleted at 800 rpm for 10 minutes in an Eppendorf 
5415C Centrifuge, washed with fresh media and pelleted 
again at 8000 rpm for 10 min. The washed pellets were 
resuspended in M9 salts media without glucose to an optical 
density ODoo-1.0. The stock solution was diluted 1:10 and 
1 ml of the diluted cell suspension was mixed with 0.1 ml 
0.1 mM Fluorescein dibutyrate (FDB) stock solution in 
dimethyl sulfoxide (DMSO). The final FDB concentration 
was 10 uM. Reactions were allowed to proceed at 37°C. for 
30 minutes. The labeled cells were immediately analyzed on 
a Becton Dickinson FACSort equipped with an Ar 488 mm 
laser. The fluorescence distribution of the cutinase express 
ing cells and the control cells is shown in FIG. 9A. 
The utility of a second probe for the discrimination 
between positive (enzyme expressing) and control cells was 
also examined. E. coli expressing cutinase from the pKG3 
53-4 plasmid, and negative cells (expressing the unmodified 
pBAD18 Cm plasmid) were grown, induced and washed as 
above. The pellet was washed with 1% sucrose, pelleted 
again, and resuspended in fresh 1% Sucrose to ODoo-1.0. 
This stock solution of cells was kept on ice. 
For labeling, a LysoSensor Green DND-189 (LSG, 
Molecular Probes) stock solution was prepared to 1 mM in 
DMSO. Also, a 1 M 4-Nitrophenyl Butyrate stock solution 
was prepared in DMSO. Cell labeling was initiated by first 
diluting the cell stock solution, adding the LSG to a final 
concentration of 1 uM and diluting the 4-Nitrophenyl 
Butyrate 1:1000 to give a final concentration of 1 uM. The 
enzymatic hydrolysis of 4-Nitrophenyl Butyrate by the cells 
was allowed to proceed at 25°C. for 5 minutes and the cells 
were then immediately analyzed on a Becton Dickinson 
FACSort as above. The fluorescence distribution of the 
cutinase expressing cells and the control cells stained with 
the LysoSensor Green DND-189 probe is shown in FIG.9B. 
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All of the methods disclosed and claimed herein can be 
made and executed without undue experimentation in light 
of the present disclosure. While the compositions and meth 
ods of this invention have been described in terms of 
preferred embodiments, it will be apparent to those of skill 
in the art that variations may be applied to the methods and 
in the steps or in the sequence of steps of the method 
described herein without departing from the concept, spirit 
and scope of the invention. More specifically, it will be 
apparent that certain agents which are both chemically and 
physiologically related may be substituted for the agents 
described herein while the same or similar results would be 
achieved. All such similar substitutes and modifications 
apparent to those skilled in the art are deemed to be within 
the spirit, scope and concept of the invention as defined by 
the appended claims. 
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SEQUENCE LISTING 




SEQ ID NO 1 
LENGTH 7 
TYPE PRT 
ORGANISM: Mus musculus 
<400 SEQUENCE: 1 
Glin Thir Thr His Wall Pro Pro 
1 5 
SEQ ID NO 2 
LENGTH 7 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE 
Peptide 
<400 SEQUENCE: 2 
Glin Thir Thr His Wall Pro Pro 
1 5 
SEQ ID NO 3 
LENGTH 7 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE 
Peptide 
<400 SEQUENCE: 3 
Glin Thir Thr His Ser Pro Ala 
1 5 
SEQ ID NO 4 
LENGTH 7 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE 
Peptide 
<400 SEQUENCE: 4 
Glin Thir Thr His Leu Pro Thr 
1 5 
<210 SEQ ID NO 5 
10 
OTHER INFORMATION: Description of Artificial Sequence: 
OTHER INFORMATION: Description of Artificial Sequence: 
OTHER INFORMATION: Description of Artificial Sequence: 
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-continued 
&2 11s LENGTH 7 
&212> TYPE PRT 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<400 SEQUENCE: 5 
Glin Thr Thr His Thr Pro Pro 
1 5 
<210> SEQ ID NO 6 
&2 11s LENGTH 7 
&212> TYPE PRT 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<400 SEQUENCE: 6 
Glin Thr Thr His Thr Pro Pro 
1 5 
<210 SEQ ID NO 7 
&2 11s LENGTH 7 
&212> TYPE PRT 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<400> SEQUENCE: 7 
Glin Thr Thr His Ile Pro Thr 
1 5 
<210 SEQ ID NO 8 
&2 11s LENGTH 7 
&212> TYPE PRT 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<400 SEQUENCE: 8 
Glin Thr Thr His Wall Pro Pro 
1 5 
<210 SEQ ID NO 9 
&2 11s LENGTH 7 
&212> TYPE PRT 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<400 SEQUENCE: 9 
Glin Thir Thr His Wall Pro Ala 
1 5 
<210> SEQ ID NO 10 
&2 11s LENGTH 7 
&212> TYPE PRT 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
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-continued 
Glin Thir Thr His Ile Pro Ala 
1 5 
<210> SEQ ID NO 11 
&2 11s LENGTH 7 
&212> TYPE PRT 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<400 SEQUENCE: 11 
Glin Thir Thr His Leu Pro Ala 
1 5 
<210> SEQ ID NO 12 
&2 11s LENGTH 7 
&212> TYPE PRT 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Peptide 
<400 SEQUENCE: 12 
Gln Thr Thr His Val Pro Cys 
1 5 
<210> SEQ ID NO 13 
&2 11s LENGTH 17 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<400 SEQUENCE: 13 
caggaalacag citatgac 
<210> SEQ ID NO 14 
&2 11s LENGTH 17 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<400 SEQUENCE: 14 
gaattittctg. tatgagg 
<210 SEQ ID NO 15 
&2 11s LENGTH 18 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
Primer 
<400 SEQUENCE: 15 
gccaccitc.cg cct galacc 
<210> SEQ ID NO 16 
&2 11s LENGTH 17 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
















citatgcggcc ccattca 17 
SEQ ID NO 17 
LENGTH 351 
TYPE DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Coding Sequence 
<400 SEQUENCE: 17 
caggtgcago tottgcagtc. to cagoagag gtgaaaaagc ccggggagtic totgaagatc 60 
to citgitaagg gttctggata cagctttacc agctactgga toggctgggit gcgc.cagatg 120 
cc.cgggaaag goctoggagtg gatggggatc atctatocto gtgacitctga taccagatac 18O 
agc.ccgto:ct tccaaggcca ggtoaccatc. tcago.cgaca agt coatcag caccgccitac 240 
citgcagtgga gcagoctogaa goc citcggac acggcc.gtgt attactgtgc aagagcttct 3OO 
cctt.cggggt ttgactattg g g gccaaggt accotggtoa cc.gtotc gag t 351 
<210> SEQ ID NO 18 
LENGTH 351 
TYPE DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Coding Sequence 
<400 SEQUENCE: 18 
gaggtgcago toggtggagtc. togggggaggc titggtcaa.gc Ctggagggit C C Ctgagactic 60 
to citgtgcag cctotggatt caccittcagt gacitactaca tagctggat cogcc aggct 120 
ccagggaagg ggctggagtg g gttt catac attagtagta gtggtag tac catatacitac 18O 
gcagacitctg tdaaggg.ccg attcaccatc. tcc agggaca acgc.caagaa citcactgitat 240 
citgcaaatga acagoctoag agcc.gaggac acggcc.gtgt attactgtgc aagaacgggit 3OO 
tittc.cggggt ttgactattg gggccaaggt accotggtoa cc.gtc.tc.gag t 351 
<210 SEQ ID NO 19 
&2 11s LENGTH 330 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Coding Sequence 
<400 SEQUENCE: 19 
cagtctgtgc tigacticagoc accotcagcg totgg gacco coggg cagag g g to accatc 60 
tottgttctg. galagcagotc caa.catcgga agtaattatg tatactggta ccago agctic 120 
ccaggaacgg ccc.ccaaact cotcatctat aggaataatc agcggcc ctic aggggtocct 18O 
gaccgattct citggcticcaa gtctggcacc toagc citccc togccatcag toggcto cqg 240 
to cqaggatg aggctgatta ttact.gtgca gcatgggatg acagoctogc g g g c tott gta 3OO 
titcggcggag ggaccalagct gaccgtocta 330 
<210> SEQ ID NO 20 
&2 11s LENGTH 330 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
FEATURE: 
52 
US 7,083,945 B1 
-continued 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Coding Sequence 
<400 SEQUENCE: 20 
cagtctgtgc tigacticagoc accotcagcg totgg gacco coggg cagag g g to accatc 60 
tottgttctg. galagcagotc caa.catcgga agtaattatg tatactggta ccago agctic 120 
ccaggaacgg ccc.ccaaact cotcatctat aggaataatc agcggcc ctic aggggtocct 18O 
gaccgattct citggcticcaa gtctggcacc toagc citccc togccatcag toggcto cqg 240 
to cqaggatg aggctgatta ttact.gtgca gcatgggatg acagoctogg g g g g to citgta 3OO 
titcggcggag ggaccalagct gaccgtocta 330 
<210> SEQ ID NO 21 
<211& LENGTH 4 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Coding Sequence 
<400 SEQUENCE: 21 
citcg 4 
<210> SEQ ID NO 22 
&2 11s LENGTH 5 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
Oligonucleotide 
<400 SEQUENCE: 22 
aaaaa. 5 
What is claimed is: 
1. A method of obtaining a bacterium comprising a 
nucleic acid sequence encoding a binding protein that binds 
a target ligand comprising the steps of 
(a) providing a Gram negative bacterium comprising a 
nucleic acid sequence encoding a candidate binding 
protein, wherein said binding protein is expressed in 
soluble form in the periplasm of said bacterium; 
(b) contacting said bacterium with a labeled ligand that 
diffuses into said periplasm; and 
(c) selecting said bacterium based on the presence of said 
labeled ligand within the periplasm, wherein said 
ligand and said candidate binding protein are bound in 
said bacterium. 
2. The method of claim 1, further comprising the step of: 
(d) cloning said nucleic acid sequence encoding said 
candidate binding protein. 
3. The method of claim 1, wherein said nucleic acid 
sequence encoding a candidate binding protein is further 
defined as operably linked to a leader sequence that directs 
expression of said candidate binding protein in said peri 
plasm. 
4. The method of claim 1, wherein said Gram negative 
bacterium is an E. coli bacterium. 
5. The method of claim 1, further defined as comprising 







6. The method of claim 5, wherein said population of 
bacteria is further defined as collectively expressing a plu 
rality of candidate binding proteins. 
7. The method of claim 6, wherein said population of 
bacteria is obtained by a method comprising the steps of 
(a) preparing a plurality of DNA inserts which collec 
tively encode a plurality of different potential binding 
proteins, and 
(b) transforming a population of Gram negative bacteria 
with said DNA inserts. 
8. The method of claim 5, wherein said population of 
Gram negative bacteria is contacted with said labeled ligand. 
9. The method of claim 1, wherein said candidate binding 
protein is further defined as an antibody or fragment thereof. 
10. The method of claim 1, wherein said candidate 
binding protein is further defined as a binding protein other 
than an antibody. 
11. The method of claim 1, wherein said candidate bind 
ing protein is further defined as an enzyme. 
12. The method of claim 1, wherein said candidate 
binding protein is further defined as not diffusing out of said 
periplasm in intact bacteria. 
13. The method of claim 1, wherein said labeled ligand 
comprises a peptide. 
14. The method of claim 1, wherein said labeled ligand 
comprises a polypeptide. 
15. The method of claim 1, wherein said labeled ligand 
comprises an enzyme. 
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16. The method of claim 1 where said labeled ligand 
comprises a nucleic acid. 
17. The method of claim 1, wherein said labeled ligand is 
further defined as comprising a molecular weight of less 
than about 20,000 Da. 
18. The method of claim 1, wherein said labeled ligand is 
further defined as comprising a molecular weight of less 
than about 5,000 Da. 
19. The method of claim 1, wherein said labeled ligand is 
further defined as comprising a molecular weight of greater 
than 600 Da and less than about 30,000 Da. 
20. The method of claim 1, wherein said labeled ligand is 
further defined as fluorescently labeled. 
21. The methods of claim 1, wherein said nucleic acid 
encoding a candidate binding protein is further defined as 
being amplified following said selection. 
22. The method of claim 1, further comprising treating 
said bacterium to facilitate diffusion of the labeled ligand 
into said periplasm. 
10 
15 
23. The method of claim 22, comprising treating the 20 
bacterium with hyperosmotic conditions. 
56 
24. The method of claim 22, comprising treating the 
bacterium with physical stress. 
25. The method of claim 23, comprising treating the 
bacterium with a phage. 
26. The method of claim 1, wherein said bacterium is 
grown at a Sub-physiological temperature. 
27. The method of claim 26, wherein said sub-physiologi 
cal temperature is about 25°C. 
28. The method of claim 1, further comprising removing 
labeled ligand not bound to said candidate binding protein. 
29. The method of claim 1, wherein said selecting com 
prises fluorescent activated cell sorting. 
30. The method of claim 1, wherein said selecting com 
prises magnetic separation. 
31. The method of claim 1, wherein said ligand and said 
candidate binding protein are reversibly bound in said 
periplasm. 
